var title_f6_40_6784="IPMN ERCP";
var content_f6_40_6784=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intraductal papillary mucinous neoplasm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 326px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Images obtained during ERCP in a 61-year-old patient with steatorrhea, weight loss, and diabetes. The left panel shows an endoscopic image of the papilla, which has a gaping \"fish eye\" appearance and is exuding mucin. The pancreatogram shows a dilated pancreatic duct and side branches with intraluminal filling defects. The patient underwent a pancreaticoduodenectomy, which confirmed an intraductal papillary mucinous neoplasm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Maurits Wiersema, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_40_6784=[""].join("\n");
var outline_f6_40_6784=null;
var title_f6_40_6785="Magnetic endoscopic imaging display monitor";
var content_f6_40_6785=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F83348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F83348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Magnetic endoscopic imaging display monitor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 403px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Monitor displaying endoscopic images from a colonoscopy alongside a panel showing the configuration of the colonoscope.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_40_6785=[""].join("\n");
var outline_f6_40_6785=null;
var title_f6_40_6786="FAST thoracic evaluation";
var content_f6_40_6786=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F59301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F59301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    FAST: Evaluation for pneumothorax",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This image of the chest, obtained during a FAST examination, reveals comet tail artifacts (indicated by arrows) extending down from the visceral pleura (P). The presence of these artifacts&nbsp;is one sign indicating the absence of a&nbsp;pneumothorax.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Greg Snead, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_40_6786=[""].join("\n");
var outline_f6_40_6786=null;
var title_f6_40_6787="Cambridge depersonalization scale";
var content_f6_40_6787=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F80001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F80001&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Cambridge depersonalization scale",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"50%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Name:",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Age:",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        <p>",
"         Sex: Male / female",
"        </p>",
"        <em>",
"         (please circle as required)",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        <p>",
"         Schooling: Primary / secondary / higher (eg, university)",
"        </p>",
"        <em>",
"         (please circle as required)",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Please read instructions carefully:",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td class=\"centered\" colspan=\"3\">",
"        This questionnaire describes strange and 'funny' experiences that normal people may have in their daily life. We are interested in their: (a)",
"        <strong>",
"         frequency",
"        </strong>",
"        , ie, how often you have had these experiences",
"        <strong>",
"         <em>",
"          over the last six months",
"         </em>",
"        </strong>",
"        and (b) their approximate",
"        <strong>",
"         duration",
"        </strong>",
"        . For each question, please circle the answers that suit you best. If you are not sure, give your best guess.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        1. Out of the blue, I feel strange, as if I were not real or as if I were cut off from the world.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        2. What I see looks 'flat' or 'lifeless', as if I were looking at a picture.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        3. Parts of my body feel as if they didn't belong to me.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        4. I have found myself",
"        <em>",
"         not being frightened at all",
"        </em>",
"        in situations which normally I would find frightening or distressing.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        5. My favourite activities are no longer enjoyable.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        6. Whilst doing something I have the feeling of being a \"detached observer\" of myself.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        7. The flavour of meals no longer gives me a feeling of pleasure or distaste.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        8. My body feels very light, as if it were floating on air.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        9. When I weep or laugh, I do not seem",
"        <em>",
"         to feel",
"        </em>",
"        any emotions at all.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        10. I have the feeling of",
"        <em>",
"         not having any thoughts at all",
"        </em>",
"        , so that when I speak it feels as if my words were being uttered by an 'automaton'.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        11. Familiar voices (including my own) sound remote and unreal.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        12. I have the feeling that my hands or my feet have become larger or smaller.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        13. My surroundings feel detached or unreal, as if there was a veil between me and the outside world.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        14. It seems as if things that I have recently done had taken place a long time ago. For example anything which I have done this morning feels as if it were done weeks ago.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        15. Whilst fully awake I have \"visions\" in which I can",
"        <em>",
"         see",
"        </em>",
"        myself outside, as if I were looking my image in a mirror.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        16. I feel detached from memories of things that have happened to me - as if I had not been involved in them.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        17. When in a new situation, it feels as if I have been through it before.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        18. Out of the blue, I find myself not feeling any affection towards my family and close friends.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        19. Objects around me seem to look smaller or further away.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        20. I cannot feel properly the objects that I touch with my hands for, it feels",
"        <em>",
"         as if it were not me",
"        </em>",
"        who were touching it.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        21. I do not seem able to picture things in my mind, for example, the face of a close friend or a familiar place.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        22. When a part of my body hurts, I feel so detached from the pain that if feels as if it were 'somebody else's pain.'",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        23. I have the feeling of being outside my body.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        24. When I move it doesn't feel as if I were in charge of the movements, so that I feel 'automatic' and mechanical as if I were a 'robot'.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        25. The smell of things no longer gives me a feeling of pleasure or dislike.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        26. I feel so detached from my thoughts that they seem to have a 'life' of their own.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        27. I have to touch myself to make sure that I have a body or a real existence.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        28.",
"        <em>",
"         I seem to have lost",
"        </em>",
"        some bodily sensations (eg, of hunger and thirst) so that when I eat or drink, it feels an automatic routine.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        29. Previously familiar places look unfamiliar, as if I had never seen them before.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <p>",
"         <strong>",
"          Frequency",
"         </strong>",
"        </p>",
"        <p>",
"         0 = Never",
"        </p>",
"        <p>",
"         1 = Rarely",
"        </p>",
"        <p>",
"         2 = Often",
"        </p>",
"        <p>",
"         3 = Very often",
"        </p>",
"        <p>",
"         4 = All the time",
"        </p>",
"       </td>",
"       <td colspan=\"2\">",
"        <p>",
"         <strong>",
"          Duration",
"         </strong>",
"         <br/>",
"         <strong>",
"          In general, it lasts:",
"         </strong>",
"        </p>",
"        <p>",
"         1 = Few seconds",
"        </p>",
"        <p>",
"         2 = Few minutes",
"        </p>",
"        <p>",
"         3 = Few hours",
"        </p>",
"        <p>",
"         4 = About a day",
"        </p>",
"        <p>",
"         5 = More than a day",
"        </p>",
"        <p>",
"         6 = More than a week",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Thank you for answering all the questions!!",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Sierra M, Berrios GE. The Cambridge Depersonalization Scale: a new instrument for the measurement of depersonalization. Psychiatry Res 2000; 93:153. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_40_6787=[""].join("\n");
var outline_f6_40_6787=null;
var title_f6_40_6788="Miglustat: Patient drug information";
var content_f6_40_6788=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Miglustat: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=see_link\">",
"     see \"Miglustat: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F196682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zavesca&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F855146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zavesca&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691857",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Gaucher's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017714\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702529",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to miglustat or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697015",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy during care and for 3 months after care ends. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shakiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695714",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11198 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-2.133.93.82-E575B2020D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_40_6788=[""].join("\n");
var outline_f6_40_6788=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F196682\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F855146\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017715\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017714\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017719\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017720\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017722\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017717\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017718\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017723\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017724\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/13/24788?source=related_link\">",
"      Miglustat: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_40_6789="Testicular sex cord stromal tumors";
var content_f6_40_6789=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Testicular sex cord stromal tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/40/6789/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/40/6789/contributors\">",
"     Mary-Ellen Taplin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/40/6789/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/40/6789/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/40/6789/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/40/6789/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/40/6789/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sex cord stromal tumors (SCSTs) comprise approximately 5 percent of all testicular tumors, while the remainder are of germ cell origin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/1\">",
"     1",
"    </a>",
"    ]. SCSTs, which arise from the supporting tissues of the testis, include Leydig, Sertoli and granulosa cell tumors, as well as malignant mesothelioma of the tunica vaginalis, adenocarcinoma of the rete testis, and paratesticular rhabdomyosarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/2-5\">",
"     2-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation and management of SCSTs is discussed here. The pathology of SCSTs and an overview of testicular germ cell tumors are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link&amp;anchor=H20#H20\">",
"     \"Anatomy and pathology of testicular tumors\", section on 'Sex cord-stromal tumors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=see_link\">",
"     \"Overview of the treatment of testicular germ cell tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common clinical presentation of testicular SCSTs is with a mass, which most often causes swelling",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    discomfort. Tumors may also be discovered on routine physical examination or during evaluation for endocrine symptoms due to sex hormone production [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/2,6\">",
"     2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no known risk factors for sex cord stromal tumors. Unlike germ cell tumors, there has been no definitive association with cryptorchidism, although such an association cannot be excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sex cord stromal tumors do not typically produce markers such as lactate dehydrogenase, alpha-fetoprotein and human chorionic gonadotropin, which are more commonly elevated in testicular germ cell tumors.",
"   </p>",
"   <p>",
"    Clinical features of specific types of SCSTs are discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Leydig cell tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leydig cell tumors are the most common testicular SCSTs. These tumors can present at any age, but are most common in adults, with a median age in two series between 40 and 50 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/2,7\">",
"     2,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Leydig cells are the principal testicular source of androgens and are also capable of estrogen production. These tumors may produce either virilizing or feminizing symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In adults, endocrine manifestations are found in 20 to 30 percent of cases, the most common of which is gynecomastia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. Other symptoms can include loss of libido, erectile dysfunction, impotence, and infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=see_link\">",
"     \"Causes and evaluation of gynecomastia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When Leydig cell tumors occur in children, precocious puberty is common [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/1\">",
"     1",
"    </a>",
"    ]. In boys with precocious puberty, Leydig cell tumor should be considered if asymmetric testicular enlargement is present. Even if a distinct mass cannot be palpated and is not detectable by ultrasonography, the larger testis should be biopsied if it enlarges during follow-up. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link&amp;anchor=H11#H11\">",
"     \"Definition, etiology, and evaluation of precocious puberty\", section on 'Boys'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Sertoli cell tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two pathologic variants of Sertoli cell tumors have been described, a large cell calcifying type and a sclerosing form. The majority of testicular Sertoli cell tumors contain features of both and cannot be assigned to either of these two categories. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link&amp;anchor=H22#H22\">",
"     \"Anatomy and pathology of testicular tumors\", section on 'Sertoli cell tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sertoli cell tumors can present at any age, with a reported mean of 45 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/3\">",
"     3",
"    </a>",
"    ]. However, patients with the large cell calcifying variant tend to be younger, with an average age at diagnosis of 21 years [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/10\">",
"     10",
"    </a>",
"    ]. Gynecomastia and other signs of hyperestrogenism are present in 20 to 30 percent of cases. In contrast to Leydig cell tumors, virilization is only rarely seen.",
"   </p>",
"   <p>",
"    Sertoli cell testicular tumors have been associated with two inherited disorders, Peutz-Jeghers syndrome and Carney's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=see_link\">",
"     \"Overview of Peutz-Jeghers syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22072?source=see_link&amp;anchor=H5#H5\">",
"     \"Cushing's syndrome due to primary pigmented nodular adrenocortical disease\", section on 'Carney complex (CNC)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Granulosa cell tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;These rare neoplasms are similar to their ovarian counterparts and are divided into adult and juvenile types. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link&amp;anchor=H23#H23\">",
"     \"Anatomy and pathology of testicular tumors\", section on 'Granulosa cell tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The adult type of granulosa cell tumor is very rare in the testis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/13\">",
"       13",
"      </a>",
"      ]. The average age at presentation is 44 years, and about one-half of reported cases have associated gynecomastia [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The juvenile type of granulosa cell tumor is the most common testicular tumor of infancy and is only rarely seen in adults [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/16\">",
"       16",
"      </a>",
"      ]. These tumors have been associated with sex chromosome abnormalities, ambiguous genitalia, and ipsilateral cryptorchidism [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/17\">",
"       17",
"      </a>",
"      ]. They appear to be uniformly benign.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other tumor types",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other stromal tumors arising in the testis include malignant mesothelioma of the tunica vaginalis, paratesticular rhabdomyosarcoma, and adenocarcinoma of the rete testis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=see_link\">",
"     \"Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radical inguinal orchiectomy is generally the procedure of choice for patients with suspected testicular cancer. The diagnostic classification of an SCST is based upon pathologic analysis of the surgical specimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33782?source=see_link&amp;anchor=H2#H2\">",
"     \"Radical inguinal orchiectomy for testicular germ cell tumors\", section on 'Surgical treatment of the testis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=see_link\">",
"     \"Anatomy and pathology of testicular tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most SCSTs are benign. However, about 10 to 20 percent of tumors in adults can metastasize and ultimately result in death. After a patient has had an inguinal orchiectomy and the diagnosis of an SCST has been established, staging evaluation should include computed tomography (CT) of the chest, abdomen, and pelvis. The presence of symptoms should determine whether other tests (eg, bone scan, neuroimaging) are indicated.",
"   </p>",
"   <p>",
"    In men with Leydig, Sertoli, or granulosa cell tumors, assessment of the",
"    <span class=\"nowrap\">",
"     pituitary/gonadal",
"    </span>",
"    axis is recommended with measurement of serum androgen, estrogen, and progesterone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/3\">",
"     3",
"    </a>",
"    ]. If any of these hormones are elevated, they may be serially evaluated as a marker of tumor response to therapy.",
"   </p>",
"   <p>",
"    The incidence of hypogonadism after orchiectomy appears to be higher in men with SCSTs than in those with germ cell tumors (42 versus 5 to 13 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/2,18\">",
"     2,18",
"    </a>",
"    ]. Thus, men with SCSTs are more likely to need testosterone replacement following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retroperitoneal lymph node dissection has been used both in patients with established nodal disease and as a staging procedure to resect any microscopic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/3,19\">",
"     3,19",
"    </a>",
"    ]. In a large single-institution series, 17 patients with SCSTs underwent RPLND [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/19\">",
"     19",
"    </a>",
"    ]. Among the nine with clinical stage I disease; retroperitoneal disease was not identified in any case, and all remained free of disease from 9 to 135 months after surgery. In the eight patients with clinical stage II or III disease, six died at 9 to 69 months after surgery, one was alive with disease at 13 months, and one was disease-free at eight months.",
"   </p>",
"   <p>",
"    The favorable prognosis for patients with clinical stage I disease is also supported by a single institution, retrospective series of 38 men, all of whom were successfully managed with excision of the primary tumor alone [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/20\">",
"     20",
"    </a>",
"    ]. At a median follow-up of seven years, none had developed metastatic disease.",
"   </p>",
"   <p>",
"    In patients with limited metastatic disease, metastasectomy should be considered because the response to chemotherapy and radiotherapy is generally poor. Radiation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapy are reserved for palliation in patients with widespread unresectable disease but response rates are low.",
"   </p>",
"   <p>",
"    Active testicular germ cell regimens, such as BEP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ) or VIP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/3/4152?source=see_link\">",
"     vinblastine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , cisplatin) have been relatively ineffective, with only transient responses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/2,19,21\">",
"     2,19,21",
"    </a>",
"    ]. The utility of newer agents such as taxanes,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , anti-angiogenic agents, and tyrosine kinase inhibitors is unknown.",
"   </p>",
"   <p>",
"    Leydig cell tumors and adrenocortical cancers have common histologic and biochemical features. There have been case reports of palliative response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    (o,p'DDD), an agent used in adrenocortical cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/2,22,23\">",
"     2,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis for patients with metastatic SCSTs is poor. Although prolonged survival has been reported, the median survival is between one and two years, and two-thirds of patients die within two years of developing metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6789/abstract/2,7,24\">",
"     2,7,24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sex cord stromal tumors (SCSTs) are rare testicular tumors that arise from the supporting tissues of the testis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all patients presenting with a testicular mass thought to be a testicular tumor, we recommend a radical inguinal orchiectomy to establish the histopathologic diagnosis and treat the primary tumor (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33782?source=see_link\">",
"       \"Radical inguinal orchiectomy for testicular germ cell tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with Leydig cell, Sertoli cell, or granulosa cell tumors, we suggest staging for evidence of metastatic disease using CT of the chest, abdomen, and pelvis and assessment of the",
"      <span class=\"nowrap\">",
"       pituitary/gonadal",
"      </span>",
"      axis, with measurement of serum androgen, estrogen, and progesterone levels (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with metastatic disease, we suggest surgical resection of all known sites of disease whenever possible (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no established role for systemic therapy, and patients with nonresectable metastatic disease should be included in clinical studies whenever possible.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/1\">",
"      Dilworth JP, Farrow GM, Oesterling JE. Non-germ cell tumors of testis. Urology 1991; 37:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/2\">",
"      Conkey DS, Howard GC, Grigor KM, et al. Testicular sex cord-stromal tumours: the Edinburgh experience 1988-2002, and a review of the literature. Clin Oncol (R Coll Radiol) 2005; 17:322.",
"     </a>",
"    </li>",
"    <li>",
"     Murthy V, Fisher C, Horwich A. Rare tumors of the testis and paratesticular tissues. In: Textbook of Uncommon Cancer, 3rd, Raghavan D, Brecher M, Johnson D, et al (Eds), Wiley, 2006. p.66.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/4\">",
"      Schure PJ, van Dalen KC, Ruitenberg HM, van Dalen T. Mesothelioma of the tunica vaginalis testis: a rare malignancy mimicking more common inguino-scrotal masses. J Surg Oncol 2006; 94:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/5\">",
"      Plas E, Riedl CR, Pfl&uuml;ger H. Malignant mesothelioma of the tunica vaginalis testis: review of the literature and assessment of prognostic parameters. Cancer 1998; 83:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/6\">",
"      Anderson MS, Brogi E, Biller BM. Occult Leydig cell tumor in a patient with gynecomastia. Endocr Pract 2001; 7:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/7\">",
"      Al-Agha OM, Axiotis CA. An in-depth look at Leydig cell tumor of the testis. Arch Pathol Lab Med 2007; 131:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/8\">",
"      Kim I, Young RH, Scully RE. Leydig cell tumors of the testis. A clinicopathological analysis of 40 cases and review of the literature. Am J Surg Pathol 1985; 9:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/9\">",
"      Gabrilove JL, Nicolis GL, Mitty HA, Sohval AR. Feminizing interstitial cell tumor of the testis: personal observations and a review of the literature. Cancer 1975; 35:1184.",
"     </a>",
"    </li>",
"    <li>",
"     Ulbright TM, Amin MB, Young RH. Ulbright TM, Amin MB, Young RH. In: Atlas of Tumor Pathology, 3rd, Rosai J, Sobin LH (Eds), Armed Forces Institute of Pathology, Washington, DC 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/11\">",
"      Proppe KH, Scully RE. Large-cell calcifying Sertoli cell tumor of the testis. Am J Clin Pathol 1980; 74:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/12\">",
"      Washecka R, Dresner MI, Honda SA. Testicular tumors in Carney's complex. J Urol 2002; 167:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/13\">",
"      Ditonno P, Lucarelli G, Battaglia M, et al. Testicular granulosa cell tumor of adult type: a new case and a review of the literature. Urol Oncol 2007; 25:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/14\">",
"      Al-Bozom IA, El-Faqih SR, Hassan SH, et al. Granulosa cell tumor of the adult type: a case report and review of the literature of a very rare testicular tumor. Arch Pathol Lab Med 2000; 124:1525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/15\">",
"      Arzola J, Hutton RL, Baughman SM, Mora RV. Adult-type testicular granulosa cell tumor: case report and review of the literature. Urology 2006; 68:1121.e13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/16\">",
"      Garrett JE, Cartwright PC, Snow BW, Coffin CM. Cystic testicular lesions in the pediatric population. J Urol 2000; 163:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/17\">",
"      Gourlay WA, Johnson HW, Pantzar JT, et al. Gonadal tumors in disorders of sexual differentiation. Urology 1994; 43:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/18\">",
"      Hansen PV, Trykker H, Andersen J, Helkjaer PE. Germ cell function and hormonal status in patients with testicular cancer. Cancer 1989; 64:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/19\">",
"      Mosharafa AA, Foster RS, Bihrle R, et al. Does retroperitoneal lymph node dissection have a curative role for patients with sex cord-stromal testicular tumors? Cancer 2003; 98:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/20\">",
"      Featherstone JM, Fernando HS, Theaker JM, et al. Sex cord stromal testicular tumors: a clinical series--uniformly stage I disease. J Urol 2009; 181:2090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/21\">",
"      Farkas LM, Sz&eacute;kely JG, Pusztai C, Baki M. High frequency of metastatic Leydig cell testicular tumours. Oncology 2000; 59:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/22\">",
"      Azer PC, Braunstein GD. Malignant Leydig cell tumor: objective tumor response to o,p'-DDD. Cancer 1981; 47:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/23\">",
"      van der Hem KG, Boven E, van Hennik MB, Pinedo HM. Malignant Leydig cell tumor of the testis in complete remission on o,p'-dichlorodiphenyl-dichloroethane. J Urol 1992; 148:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6789/abstract/24\">",
"      Grem JL, Robins HI, Wilson KS, et al. Metastatic Leydig cell tumor of the testis. Report of three cases and review of the literature. Cancer 1986; 58:2116.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2972 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-393BA8AD0C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_40_6789=[""].join("\n");
var outline_f6_40_6789=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Leydig cell tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Sertoli cell tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Granulosa cell tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other tumor types",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/40/5770?source=related_link\">",
"      Anatomy and pathology of testicular tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=related_link\">",
"      Causes and evaluation of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/35/22072?source=related_link\">",
"      Cushing's syndrome due to primary pigmented nodular adrenocortical disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/6/37990?source=related_link\">",
"      Overview of Peutz-Jeghers syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/7/13432?source=related_link\">",
"      Overview of the treatment of testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/63/33782?source=related_link\">",
"      Radical inguinal orchiectomy for testicular germ cell tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16377?source=related_link\">",
"      Rhabdomyosarcoma and undifferentiated sarcoma in childhood and adolescence: Epidemiology, pathology, and molecular pathogenesis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_40_6790="DEB3";
var content_f6_40_6790=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86596&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Recessive dystrophic epidermolysis bullosa (DEB)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large, nonhealing erosions and ulcers with partly impetiginized crusts in severe generalized recessive dystrophic EB.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_40_6790=[""].join("\n");
var outline_f6_40_6790=null;
var title_f6_40_6791="Button battery removed from the nose";
var content_f6_40_6791=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Button battery removed from the nose",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This button battery was removed from the nose and shows necrotic tissue attached to the negative pole.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_40_6791=[""].join("\n");
var outline_f6_40_6791=null;
var title_f6_40_6792="Darier forehead";
var content_f6_40_6792=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Darier's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_40_6792=[""].join("\n");
var outline_f6_40_6792=null;
var title_f6_40_6793="Guidelines for prescribing clozapine in schizophrenia";
var content_f6_40_6793=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Guidelines for prescribing clozapine in schizophrenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/40/6793/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/40/6793/contributors\">",
"     Joseph McEvoy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/40/6793/contributors\">",
"     Oliver Freudenreich, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/40/6793/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/40/6793/contributors\">",
"     Stephen Marder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/40/6793/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/40/6793/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/40/6793/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H20931793\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    has been found to be an effective treatment in persons with schizophrenia resistant to treatment with other antipsychotic drugs. In addition, clozapine is an effective treatment for schizophrenia accompanied by persistent suicidal or self-injurious behavior. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link&amp;anchor=H108920615#H108920615\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\", section on 'Clozapine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    &rsquo;s unique side effect profile, which includes a low rate of life-threatening agranulocytosis, gives rise to numerous considerations in prescribing, monitoring, and side effect management in the use of the drug.",
"   </p>",
"   <p>",
"    This topic describes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    &rsquo;s pharmacology, indications and contraindications in schizophrenia, administration (including dosing and monitoring), and adverse effects. The efficacy of clozapine in schizophrenia is discussed separately. Clozapine is compared with other antipsychotic drugs separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link&amp;anchor=H108920615#H108920615\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\", section on 'Clozapine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link&amp;anchor=H76524735#H76524735\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\", section on 'Clozapine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20931856\">",
"    <span class=\"h1\">",
"     INDICATIONS AND CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary indications for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    include its use in persons with schizophrenia or schizoaffective disorder resistant to treatment with other antipsychotic drugs, or",
"    <span class=\"nowrap\">",
"     schizophrenia/schizoaffective",
"    </span>",
"    accompanied by persistent suicidal or self-injurious behavior.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    is absolutely contraindicated in cases of a prior history of clozapine-induced agranulocytosis or clozapine-induced myocarditis. Other conditions, below, are relative contraindications where the risks, benefits, and alternatives to clozapine must be weighed for each patient. The adverse effects of clozapine vary in their severity, as do the drug&rsquo;s benefits, which range from reducing psychosis to potentially life-saving in a patient with schizophrenia at risk of suicide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98146982\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with a seizure disorder should have their seizures optimally controlled before",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    is started. They should be observed carefully as clozapine is initiated. A follow-up electroencephalogram may be indicated after clozapine treatment is established.",
"   </p>",
"   <p>",
"    Patients with an elevated seizure risk, including those with a history of febrile seizures or epilepsy, should be considered for prophylactic treatment with an anticonvulsant drug when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    is initiated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=see_link&amp;anchor=H3#H3\">",
"     \"Status epilepticus in adults\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98146995\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with pre-existing neutropenia, such as from a bone marrow disorder (eg, myeloproliferative disease) or from other drugs that can cause bone marrow toxicity (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ), may be difficult to treat with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    because of chronically low absolute neutrophil counts that trigger alerts and mandatory discontinuation of clozapine according to registry requirements. Carbamazepine should be avoided in patients taking clozapine. (See",
"    <a class=\"local\" href=\"#H20931954\">",
"     'Agranulocytosis'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98147064\">",
"    <span class=\"h2\">",
"     Heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with pre-existing heart disease are at greater risk of morbidity from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    -induced myocarditis; they have less cardiac reserve should any, even temporary, cardiac damage and malfunction occur during the initiation of clozapine. In such individuals, clozapine should be initiated in the inpatient setting with close monitoring of cardiac function. (See",
"    <a class=\"local\" href=\"#H20931961\">",
"     'Myocarditis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98147085\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals with obesity, diabetes mellitus, dyslipidemias, or atherosclerotic cardiovascular disease may have worsening of these disorders when treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    and more aggressive treatment of these disorders will be required. Monitoring of lipids and indicators of insulin resistance is indicated in all patients treated with clozapine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207140\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacologic mechanisms underlying",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    &rsquo;s superiority for treatment-resistant schizophrenia are not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207147\">",
"    <span class=\"h2\">",
"     Pharmacodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    binds loosely and transiently to dopamine D2 receptors. Clozapine does not induce catalepsy or inhibit apomorphine-induced stereotypy in animal models as is seen with conventional antipsychotic medications; this may explain its reduced potential for producing movement abnormalities relative to tightly binding dopamine D2 antagonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    . Clozapine also binds to D1, D3, and D5 receptors, and has a high affinity for the D4 receptor, but the implications of these binding activities are unclear.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    also interacts at histamine H1, acetylcholine muscarinic M1 and serotonin 5-HT2A, 5-HT2C, 5-HT6, and 5-HT7 receptors, and at alpha-1-adrenoceptors. Postural dizziness, sedation, and increased appetite may reflect actions of clozapine at alpha-1, H1, and 5-HT2c receptors, respectively. Actions at the 5-HT2A and M1 receptors may reduce movement side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207154\">",
"    <span class=\"h2\">",
"     Pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    is well absorbed. First-pass metabolism reduces its bio-availability to 60 to 70 percent of the administered dose; food has little effect on the bioavailability of clozapine. The elimination half-life of clozapine averages approximately 14 hours under steady state conditions, but there is substantial variability across individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    is extensively metabolized by the cytochrome P450 system in the liver, and excreted in both the urine and feces. Cytochrome P450 1A2 is primarily responsible for clozapine metabolism; cytochromes 2C, 2D6, and",
"    <span class=\"nowrap\">",
"     3A3/4",
"    </span>",
"    play less important roles. Agents that induce cytochrome CYP1A2, such as tobacco cigarette smoke, will increase the metabolism of clozapine. Tobacco smokers may require twice the dose of non-smokers to achieve similar blood levels. Agents that inhibit CYP1A2 (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/50/29481?source=see_link\">",
"     fluvoxamine",
"    </a>",
"    ) will decrease the metabolism of clozapine and may produce clinical toxicity at usual doses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/3\">",
"     3",
"    </a>",
"    ]. Cytochrome-related problems can be avoided by monitoring clozapine plasma levels while gradually increasing clozapine from a low starting dose. (See",
"    <a class=\"local\" href=\"#H20931863\">",
"     'Dosing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The major metabolite of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , norclozapine (desmethyl-clozapine), has failed to demonstrate any therapeutic activity in clinical trials. Clozapine and norclozapine plasma levels are both reported by clinical labs, but only the clozapine level is useful for dose optimization [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20932047\">",
"    <span class=\"h1\">",
"     ADMINISTRATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98147235\">",
"    <span class=\"h2\">",
"     Pre-treatment assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment prior to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    should include evaluation of the patient&rsquo;s general and cardiovascular health status and a baseline complete blood count and absolute neutrophil (ANC) count. A white blood count (WBC) &ge;",
"    <span class=\"nowrap\">",
"     3500/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and ANC &ge;",
"    <span class=\"nowrap\">",
"     2000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    are acceptable for initiating clozapine. Patients should also have a baseline weight and height recorded (BMI), waist circumference as well as fasting blood sugar (or HbA1c) and fasting lipids. Patients on anticonvulsant drugs need to be in the therapeutic range. Baseline vital signs should be obtained. A baseline ECG should be obtained. Absence or presence of abnormal motor movements should be documented using the Abnormal Involuntary Movement Scale (AIMS) (",
"    <a class=\"graphic graphic_form graphicRef51103 \" href=\"UTD.htm?43/13/44243\">",
"     form 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H20931975\">",
"     'Weight gain'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20931982\">",
"     'Insulin resistance and diabetes mellitus'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H20931989\">",
"     'Seizures'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H3912828\">",
"     'Movement disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20931863\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    usually commences at a low dose (12.5 to 25",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    During the initial titration in inpatient settings, twice or three time daily dosing is typically employed to reduce autonomic side effects like orthostatic hypotension and take advantage of clozapine&rsquo;s sedating effects. If well tolerated, the dose can be increased gradually, typically by 12.5 to 25 mg every one to two days, with the target dose and frequency determined by the plasma clozapine level and adverse effects. A clozapine plasma level can be checked after an initial target dose is reached, generally after two weeks in the inpatient setting. Given the pharmacokinetics of clozapine, differences of a few hours in the time of evening dosing",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    morning plasma sampling will lead to large differences in reported plasma levels. Orthostatic blood pressure should be monitored daily when feasible (ie, in inpatient setting).",
"   </p>",
"   <p>",
"    A",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    plasma level in the range of 250 to 350",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    is a reasonable target for a patient with schizophrenia, but patients show great variation in both their symptomatic response and side effects. Once the target dose is reached, the patient&rsquo;s clinical response should be monitored for two weeks before a further increase. There is little evidence to suggest greater efficacy at blood levels greater than 350",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    but outliers may exist.",
"   </p>",
"   <p>",
"    A maintenance dose of 300 to 600",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    is usually required for efficacy. Doses higher than 900",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    are not recommended. In the elderly and medically ill population, the titration may need to be slower, and maintenance doses are typically in the 100 to 150",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    range. However, due to great interindividual variability in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    metabolism, rare patients can reach toxic levels with low doses like 100",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and some patients fail to achieve therapeutic levels with 900",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    Once the patient is stabilized on an effective maintenance dose, all or most of the daily dose may be given at bedtime. This will aid patients in getting to sleep and avoiding daytime sedation. Compliance can be improved by taking the medication at the time of routine, consistent behaviors, such as breakfast or bedtime preparations, and by prescribing once or twice daily rather than more frequently. However, some patients require split doses to avoid bed wetting or morning grogginess.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98147514\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207044\">",
"    <span class=\"h3\">",
"     White blood count",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Food and Drug Administration in the United States requires that patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    be entered into a computer-based registry and that regular monitoring of the patient&rsquo;s WBC and absolute neutrophil (ANC) count precede dispensing of the drug and continue as long as a patient receives clozapine. WBC monitoring is performed at the following intervals:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Weekly during the first six months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      administration",
"     </li>",
"     <li>",
"      Every other week for the second six months",
"     </li>",
"     <li>",
"      Every four weeks after one year, for the duration of treatment",
"     </li>",
"     <li>",
"      For an additional month after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      is stopped",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A WBC &ge;",
"    <span class=\"nowrap\">",
"     3500/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    and ANC &ge;",
"    <span class=\"nowrap\">",
"     2000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    are acceptable for initiating and continuing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    . Should leukopenia or granulocytopenia develop during treatment, clozapine either has to be monitored more frequently, stopped temporarily, or discontinued, based on the severity of the result:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild",
"      <span class=\"nowrap\">",
"       leukopenia/granulocytopenia",
"      </span>",
"      (WBC 3500 to 3000; ANC 2000 to 1500) &mdash; Frequency of monitoring is increased to twice weekly.",
"     </li>",
"     <li>",
"      Moderate",
"      <span class=\"nowrap\">",
"       leukopenia/granulocytopenia",
"      </span>",
"      (WBC 3000 to 2000; ANC 1500 to 1000) &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       Clozapine",
"      </a>",
"      treatment is interrupted until",
"      <span class=\"nowrap\">",
"       leukopenia/granulocytopenia",
"      </span>",
"      resolves.",
"     </li>",
"     <li>",
"      Severe",
"      <span class=\"nowrap\">",
"       leukopenia/agranulocytosis",
"      </span>",
"      (WBC &lt;2000; ANC &lt;1000) &mdash;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       Clozapine",
"      </a>",
"      is discontinued without the possibility of a rechallenge.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This WBC monitoring schedule has been successful in allowing safe use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    by avoiding deaths due to agranulocytosis.",
"   </p>",
"   <p>",
"    To avoid unintentional repeat use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    with patients who have previously developed agranulocytosis while on the drug, several manufacturers require patients and prescribing clinicians to be entered into a database before treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H207056\">",
"    <span class=\"h3\">",
"     Cardiovascular",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because in rare cases",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    -induced myocarditis can progress rapidly into cardiomyopathy and congestive heart failure, all patients should be monitored closely for at least the initial four weeks of treatment. This should include assessment of clinical status for subjective signs of distress, vital signs each visit, electrocardiogram at baseline, and then weekly laboratory tests including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Eosinophil count",
"     </li>",
"     <li>",
"      Sedimentation rate or C-reactive protein",
"     </li>",
"     <li>",
"      Troponins",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20932063\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20931954\">",
"    <span class=\"h2\">",
"     Agranulocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of agranulocytosis in a study of 12,760 patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    was approximately 0.8 percent; leukopenia occurred in almost 3 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/5\">",
"     5",
"    </a>",
"    ]. The peak risks for both occurred early in treatment, between 6 to 18 weeks from initiation. Advancing age was a risk factor for agranulocytosis in this cohort. Regular blood monitoring over a five-year period has been estimated to reduce the risk of agranulocytosis from approximately 1 to 2 percent to 0.38 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Due to the categorical WBC and ANC cut-offs used to monitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    treatment, patients with benign ethnic neutropenia (often seen in patients of African descent) can be either ineligible for a clozapine trial because of habitually low WBC counts or are subjected to more frequent blood draws. This may contribute to lower rates of clozapine initiation and treatment that have been observed among African-Americans in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/7\">",
"     7",
"    </a>",
"    ]. Clinical reports suggest that in cases of benign ethnic neutropenia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    can be added to increase the granulocyte count above the required dispensing threshold [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H98147514\">",
"     'Monitoring'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=see_link\">",
"     \"Overview of neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If agranulocytosis occurs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     filgrastim",
"    </a>",
"    hastens the return to normal WBC and ANC counts [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], although it is not clear this alters infection rates or mortality. Patients who have experienced an episode of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    -induced agranulocytosis should not be re-challenged as the majority of cases will quickly develop agranulocytosis again. In one study of 53 patients who had experienced leukopenia or neutropenia from clozapine, 20 patients developed another blood dyscrasia that was more severe and occurred more rapidly upon rechallenge [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    in patients with pre-existing neutropenia is discussed above. (See",
"    <a class=\"local\" href=\"#H98146995\">",
"     'Neutropenia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20931961\">",
"    <span class=\"h2\">",
"     Myocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have estimated the risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    -induced myocarditis to be",
"    <span class=\"nowrap\">",
"     1/500",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/10,000",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/13\">",
"     13",
"    </a>",
"    ]. The true risk is likely closer to the",
"    <span class=\"nowrap\">",
"     1/500",
"    </span>",
"    rate, as often only a minority of adverse medication-related events are diagnosed and reported.",
"   </p>",
"   <p>",
"    Most cases of myocarditis occur early in the course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    treatment. The condition developed within a median of 16 days of initiating clozapine in a study of 116 cases, [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/13\">",
"     13",
"    </a>",
"    ]. Approximately 80 percent of cases of clozapine-induced myocarditis occur within four weeks of drug initiation, and 90 percent occur within eight weeks.",
"   </p>",
"   <p>",
"    Post-mortem examination has most commonly revealed damaged myocytes and eosinophilic infiltration suggesting a type I Ig E-mediated acute hypersensitivity reaction. The time of onset of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    -induced myocarditis and the pathological findings support this hypothesis. Other contributing mechanisms may include cytokine release and high levels of catecholamines.",
"   </p>",
"   <p>",
"    A typical pattern of unspecific clinical symptoms (fever, tachycardia) and laboratory findings (elevated eosinophil count, sedimentation rate or c-reactive protein, troponins, creatine phospho-kinase, and brain natriuretic peptide), combined with a high index of suspicion in a patient started on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    within the past four to eight weeks is needed to diagnose myocarditis in a clozapine patient.",
"   </p>",
"   <p>",
"    A diagnosis of myocarditis should be followed by prompt discontinuation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    and medical follow-up with the patient&rsquo;s PCP for supportive treatment. This course will usually lead to spontaneous resolution. Subsequent use of clozapine is contraindicated in cases with clear clozapine-induced myocarditis because most patients experience recurrence of myocarditis when the drug is restarted.",
"   </p>",
"   <p>",
"    Use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    in patients with pre-existing heart disease, and monitoring of patients at the initiation of clozapine treatment, are discussed above. (See",
"    <a class=\"local\" href=\"#H98147064\">",
"     'Heart disease'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H207056\">",
"     'Cardiovascular'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20931968\">",
"    <span class=\"h2\">",
"     Pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    has been associated with an increased risk of venous thromboembolic events including pulmonary embolism leading to death [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/14-20\">",
"     14-20",
"    </a>",
"    ]. Of the published cases with a known outcome, the mortality rate of a clotting complication while on clozapine was 44 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for thromboembolic disease in the general population include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Genetic factors (mainly the factor V Leiden mutation or a high concentration of factor VIII)",
"     </li>",
"     <li>",
"      Recent immobilization",
"     </li>",
"     <li>",
"      Recent surgery",
"     </li>",
"     <li>",
"      Pregnancy or the postpartum state",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians starting patients on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    should advise recipients to remain physically active.",
"   </p>",
"   <p>",
"    Although prophylactic use to prevent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    -associated venous thrombosis of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and statins has not been studied in patients receiving clozapine, aspirin has been shown to reduce the risk of venous thromboembolism in patients undergoing orthopedic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/22\">",
"     22",
"    </a>",
"    ], and statins have been shown to reduce venous thromboembolism among individuals receiving chemotherapy for cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/23\">",
"     23",
"    </a>",
"    ]. The routine use of these agents among individuals without contraindications may reduce risk of venous thromboembolism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20931975\">",
"    <span class=\"h2\">",
"     Weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    can cause significant weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/24-28\">",
"     24-28",
"    </a>",
"    ]. The average weight gain in a 10-year cohort study of clozapine was 30 pounds [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/24\">",
"     24",
"    </a>",
"    ]. While most weight gain occurs during the first 6 to 12 months, some patients continue to gain weight without reaching a plateau [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/26\">",
"     26",
"    </a>",
"    ]. Weight should be routinely monitored and behavioral interventions recommended if patients gain weight on clozapine.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     Metformin",
"    </a>",
"    has been used to blunt antipsychotic-induced weight gain and improve insulin sensitivity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link&amp;anchor=H28219066#H28219066\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\", section on 'Clinical management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20931982\">",
"    <span class=\"h2\">",
"     Insulin resistance and diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of 96 patients with chronic schizophrenia treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    and followed for up to 10 years, 34 percent developed diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/24\">",
"     24",
"    </a>",
"    ]. The progressive increases in obesity, diabetes, elevated triglycerides, and hypertension in their population resulted in substantially increased cardiovascular risk. The insulin resistance from clozapine treatment is at least in part independent from clozapine-induced weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/30\">",
"     30",
"    </a>",
"    ]. Screening for diabetes at six-month intervals or more frequently (ie, fasting blood sugar) should be done. HbA1c can be used if obtaining fasting blood sugar levels is unreliable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=see_link\">",
"     \"Screening for diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20931989\">",
"    <span class=\"h2\">",
"     Seizures",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    is associated with a dose-dependent seizure risk at a rate higher than that seen with most other antipsychotic drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In a review of 1418 patients treated with clozapine, the cumulative seizure risk was estimated to be 10 percent after 3.8 years of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/33\">",
"     33",
"    </a>",
"    ]. Higher doses of clozapine were associated with a greater rate of seizures:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      600",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or more &mdash; 4.4 percent",
"     </li>",
"     <li>",
"      300 to 600",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      &mdash; 2.7 percent",
"     </li>",
"     <li>",
"      300",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      or less &mdash; 1.0 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a review of 101 patients experiencing a seizure while receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , the most frequently described type of seizure was tonic-clonic; together with",
"    <span class=\"nowrap\">",
"     myoclonic/atonic",
"    </span>",
"    seizures, they comprise about one-quarter of reported seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/34\">",
"     34",
"    </a>",
"    ]. The mean clozapine dosage in the cohort was less than 600 mg per day.",
"   </p>",
"   <p>",
"    The implications of a pre-existing seizure disorder and treatment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    -induced seizures are discussed separately. (See",
"    <a class=\"local\" href=\"#H98146982\">",
"     'Seizures'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=see_link\">",
"     \"Initial treatment of epilepsy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20931996\">",
"    <span class=\"h2\">",
"     Excessive salivation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    -induced hypersalivation is a common side effect that can be treatment-limiting as patients are unable to tolerate incessant drooling that is stigmatizing during the day and hinders sleeping at night. It often occurs at low doses [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/35\">",
"     35",
"    </a>",
"    ], and can worsen during sleep. Its mechanism is thought to be due to a disturbance of deglutition and not merely an increase in salivary flow rate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A reduction in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    dose can be tried to limit salivation, but this step alone is often inadequate. Among treatment options,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/20/11591?source=see_link\">",
"     glycopyrrolate",
"    </a>",
"    at a dose of 2 to 4 mg given at night is a good initial choice. A randomized trial compared glycopyrrolate to biperiden [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/37\">",
"     37",
"    </a>",
"    ]. While both were associated with a reduced rate of drooling, a larger decrease was seen in the group taking glycopyrrolate. Glycopyrrolate does not penetrate the blood-brain barrier, thus avoiding central anticholinergic effects such as impairment of memory. However, it adds to clozapine&rsquo;s already significant intrinsic peripheral anticholinergic burden. (See",
"    <a class=\"local\" href=\"#H20932010\">",
"     'Constipation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other treatment approaches, based on case reports or case series, include the use of sugarless chewing gum to increase the rate of swallowing, anticholinergic agents (eg, 5 to 15",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/1/6165?source=see_link\">",
"     trihexyphenidyl",
"    </a>",
"    ), or alpha-2 agonists (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"     clonidine",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20932003\">",
"    <span class=\"h2\">",
"     Urinary incontinence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    appears to be associated with an increased incidence of urinary incontinence, hypothesized to be related to the potent anti-alpha-adrenergic effects of clozapine. An open trial of 16 patients suggested that ephedrine, an alpha-adrenergic agonist, may be highly effective in treating clozapine induced urinary incontinence, supporting the hypothesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/38\">",
"     38",
"    </a>",
"    ]. A dose of 25 mg ephedrine at night or 25 mg twice daily is often sufficient to treat urinary incontinence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20932010\">",
"    <span class=\"h2\">",
"     Constipation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Constipation has been reported to occur in approximately 14 percent of patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , and can be severe [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/39\">",
"     39",
"    </a>",
"    ]. This is most likely due to the drug&rsquo;s anticholinergic properties [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/40\">",
"     40",
"    </a>",
"    ]; other medications with anticholinergic properties may exacerbate it.",
"   </p>",
"   <p>",
"    Severe constipation, culminating in adynamic ileus, can be fatal. In a report of 102 cases of life-threatening gastrointestinal hypomotility suspected to be caused by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    , considerable mortality was seen (largely due to bowel resection) along with a mortality rate of 27.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/41\">",
"     41",
"    </a>",
"    ]. Probable risk factors included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Recent initiation of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"     </li>",
"     <li>",
"      High",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      doses or serum levels",
"     </li>",
"     <li>",
"      Use of other drugs with anticholinergic activity",
"     </li>",
"     <li>",
"      Comorbid medical illness.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a retrospective analysis of diagnostic and pharmacy data on 26,720 inpatients with schizophrenia over an 11-year period, 123 cases of ileus were observed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/42\">",
"     42",
"    </a>",
"    ]. Female sex and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    treatment were associated with an increased risk of ileus. Nine of the ileus cases (7.3 percent) had a fatal course, with clozapine treatment and anticholinergic use associated with lethality. The onset of ileus occurred on average more than three years after the first prescription of the offending drug.",
"   </p>",
"   <p>",
"    Patients receiving psychotropics associated with significant anticholinergic properties should undergo proper clinical monitoring and interventions in order to minimize the burden of constipation and the risk of ileus. Patients can be encouraged to eat a diet high in fiber, drink plenty of fluids, and exercise. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30616?source=see_link\">",
"     \"Management of chronic constipation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20932017\">",
"    <span class=\"h2\">",
"     Sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     Clozapine",
"    </a>",
"    can cause significant sedation, particularly during the initiation of treatment. Tolerability of the sedating effect can be enhanced by gradually titrating to a therapeutic dose. Some clinicians add stimulants or stimulant-like drugs if patients continue to experience sedation. However, two small randomized trials in patients with clozapine-induced sedation found no benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/8/1159?source=see_link\">",
"     modafinil",
"    </a>",
"    (200 to 300",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    on measures of fatigue or wakefulness [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19303378\">",
"    <span class=\"h2\">",
"     Teratogenic and neonatal risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no definitive association has been found between use of antipsychotic medications during pregnancy and an increased risk of birth defects or other adverse outcomes, there is a paucity of information, with a lack of large, well designed, prospective studies. Second-generation antipsychotics cross the placenta [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=see_link&amp;anchor=H1561513#H1561513\">",
"     \"Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy\", section on 'Second-generation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27026146\">",
"    <span class=\"h2\">",
"     Mortality risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The US Food and Drug Administration (FDA) has reported that the use of first- and second-generation antipsychotic medications for the treatment of behavioral symptoms in elderly patients with dementia is associated with increased mortality [",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/treatment-of-behavioral-symptoms-related-to-dementia/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link&amp;anchor=H15#H15\">",
"     \"Treatment of behavioral symptoms related to dementia\", section on 'Serious adverse events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3912828\">",
"    <span class=\"h2\">",
"     Movement disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Compared to other antipsychotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    has a reduced risk of causing tardive dyskinesia or extrapyramidal movement disorders including akathisia. However, patients can still develop these movement disorders and need to be monitored for their development (eg, standardized motor exam with the Abnormal Involuntary Movement Scale [AIMS] every six months) (",
"    <a class=\"graphic graphic_form graphicRef51103 \" href=\"UTD.htm?43/13/44243\">",
"     form 1",
"    </a>",
"    ). Despite clozapine&rsquo;s weak affinity for the dopamine receptor, the neuroleptic malignant syndrome (NMS) can develop [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6793/abstract/46\">",
"     46",
"    </a>",
"    ] (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34952?source=see_link\">",
"     \"Tardive dyskinesia: Prevention and treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H350566201\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary indications for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      include its use in persons with schizophrenia or schizoaffective disorder resistant to treatment with other antipsychotic drugs, or",
"      <span class=\"nowrap\">",
"       schizophrenia/schizoaffective",
"      </span>",
"      accompanied by persistent suicidal or self-injurious behavior. (See",
"      <a class=\"local\" href=\"#H20931856\">",
"       'Indications and contraindications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link&amp;anchor=H108920615#H108920615\">",
"       \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\", section on 'Clozapine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       Clozapine",
"      </a>",
"      is absolutely contraindicated in cases of a prior history of clozapine-induced agranulocytosis or myocarditis (See",
"      <a class=\"local\" href=\"#H20931856\">",
"       'Indications and contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Assessment of patients prior to starting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      should include (See",
"      <a class=\"local\" href=\"#H98147235\">",
"       'Pre-treatment assessment'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      General and cardiovascular health status",
"     </li>",
"     <li>",
"      Complete blood count with an absolute neutrophil count",
"     </li>",
"     <li>",
"      Weight, height, body mass index, and waist circumference",
"     </li>",
"     <li>",
"      Fasting blood sugar or HbA1c",
"     </li>",
"     <li>",
"      Fasting lipids",
"     </li>",
"     <li>",
"      Vital signs",
"     </li>",
"     <li>",
"      ECG",
"     </li>",
"     <li>",
"      Absence or presence of abnormal motor movements (",
"      <a class=\"graphic graphic_form graphicRef51103 \" href=\"UTD.htm?43/13/44243\">",
"       form 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A maintenance dose of 300 to 600",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      is usually required for efficacy. Doses higher than 900",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      are not recommended. In the elderly and medically ill population, the titration may need to be slower, and maintenance doses are typically in the 100 to 150",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      range. (See",
"      <a class=\"local\" href=\"#H20931863\">",
"       'Dosing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      should receive routine weekly-to-monthly monitoring and maintain a white blood count",
"      <span class=\"nowrap\">",
"       &ge;3500/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      and an absolute neutrophil count",
"      <span class=\"nowrap\">",
"       &ge;2000/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H207044\">",
"       'White blood count'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potentially severe adverse effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"       clozapine",
"      </a>",
"      include agranulocytosis, myocarditis, pulmonary embolism, diabetes mellitus, seizures, and adynamic ileus. (See",
"      <a class=\"local\" href=\"#H20932063\">",
"       'Adverse effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/1\">",
"      Gardner DM, Baldessarini RJ, Waraich P. Modern antipsychotic drugs: a critical overview. CMAJ 2005; 172:1703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/2\">",
"      Jann MW, Grimsley SR, Gray EC, Chang WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinet 1993; 24:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/3\">",
"      Prior TI, Baker GB. Interactions between the cytochrome P450 system and the second-generation antipsychotics. J Psychiatry Neurosci 2003; 28:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/4\">",
"      VanderZwaag C, McGee M, McEvoy JP, et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/5\">",
"      Munro J, O'Sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 1999; 175:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/6\">",
"      Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59 Suppl 3:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/7\">",
"      Kelly DL, Kreyenbuhl J, Dixon L, et al. Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull 2007; 33:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/8\">",
"      Boshes RA, Manschreck TC, Desrosiers J, et al. Initiation of clozapine therapy in a patient with preexisting leukopenia: a discussion of the rationale of current treatment options. Ann Clin Psychiatry 2001; 13:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/9\">",
"      Nykiel S, Henderson D, Bhide G, Freudenreich O. Lithium to allow clozapine prescribing in benign ethnic neutropenia. Clin Schizophr Relat Psychoses 2010; 4:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/10\">",
"      Nielsen H. Recombinant human granulocyte colony-stimulating factor (rhG-CSF; filgrastim) treatment of clozapine-induced agranulocytosis. J Intern Med 1993; 234:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/11\">",
"      Lamberti JS, Bellnier TJ, Schwarzkopf SB, Schneider E. Filgrastim treatment of three patients with clozapine-induced agranulocytosis. J Clin Psychiatry 1995; 56:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/12\">",
"      Dunk LR, Annan LJ, Andrews CD. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy. Br J Psychiatry 2006; 188:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/13\">",
"      Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007; 30:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/14\">",
"      Walker AM, Lanza LL, Arellano F, Rothman KJ. Mortality in current and former users of clozapine. Epidemiology 1997; 8:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/15\">",
"      H&auml;gg S, Spigset O, S&ouml;derstr&ouml;m TG. Association of venous thromboembolism and clozapine. Lancet 2000; 355:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/16\">",
"      Kortepeter C, Chen M, Knudsen JF, et al. Clozapine and venous thromboembolism. Am J Psychiatry 2002; 159:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/17\">",
"      Ihde-Scholl T, Rolli ML, Jefferson JW. Clozapine and pulmonary embolus. Am J Psychiatry 2001; 158:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/18\">",
"      Farah RE, Makhoul NM, Farah RE, Shai MD. Fatal venous thromboembolism associated with antipsychotic therapy. Ann Pharmacother 2004; 38:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/19\">",
"      Yang TY, Chung KJ, Huang TL, Kung CT. Massive pulmonary embolism in a young patient on clozapine therapy. J Emerg Med 2004; 27:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/20\">",
"      Liperoti R, Pedone C, Lapane KL, et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005; 165:2677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/21\">",
"      Paciullo CA. Evaluating the association between clozapine and venous thromboembolism. Am J Health Syst Pharm 2008; 65:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/22\">",
"      Marsland D, Mears SC, Kates SL. Venous thromboembolic prophylaxis for hip fractures. Osteoporos Int 2010; 21:S593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/23\">",
"      Khemasuwan D, Divietro ML, Tangdhanakanond K, et al. Statins decrease the occurrence of venous thromboembolism in patients with cancer. Am J Med 2010; 123:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/24\">",
"      Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005; 66:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/25\">",
"      Lamberti JS, Bellnier T, Schwarzkopf SB. Weight gain among schizophrenic patients treated with clozapine. Am J Psychiatry 1992; 149:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/26\">",
"      Umbricht DS, Pollack S, Kane JM. Clozapine and weight gain. J Clin Psychiatry 1994; 55 Suppl B:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/27\">",
"      Bai YM, Lin CC, Chen JY, et al. Association of initial antipsychotic response to clozapine and long-term weight gain. Am J Psychiatry 2006; 163:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/28\">",
"      Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2009; 70:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/29\">",
"      Carrizo E, Fern&aacute;ndez V, Connell L, et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res 2009; 113:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/30\">",
"      Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005; 62:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/31\">",
"      Pacia SV, Devinsky O. Clozapine-related seizures: experience with 5,629 patients. Neurology 1994; 44:2247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/32\">",
"      Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007; 62:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/33\">",
"      Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991; 41:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/34\">",
"      Wong J, Delva N. Clozapine-induced seizures: recognition and treatment. Can J Psychiatry 2007; 52:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/35\">",
"      Freudenreich O. Drug-induced sialorrhea. Drugs Today (Barc) 2005; 41:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/36\">",
"      Rabinowitz T, Frankenburg FR, Centorrino F, Kando J. The effect of clozapine on saliva flow rate: a pilot study. Biol Psychiatry 1996; 40:1132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/37\">",
"      Liang CS, Ho PS, Shen LJ, et al. Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. Schizophr Res 2010; 119:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/38\">",
"      Fuller MA, Borovicka MC, Jaskiw GE, et al. Clozapine-induced urinary incontinence: incidence and treatment with ephedrine. J Clin Psychiatry 1996; 57:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/39\">",
"      Young CR, Bowers MB Jr, Mazure CM. Management of the adverse effects of clozapine. Schizophr Bull 1998; 24:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/40\">",
"      Hayes G, Gibler B. Clozapine-induced constipation. Am J Psychiatry 1995; 152:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/41\">",
"      Palmer SE, McLean RM, Ellis PM, Harrison-Woolrych M. Life-threatening clozapine-induced gastrointestinal hypomotility: an analysis of 102 cases. J Clin Psychiatry 2008; 69:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/42\">",
"      Nielsen J, Meyer JM. Risk factors for ileus in patients with schizophrenia. Schizophr Bull 2012; 38:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/43\">",
"      Freudenreich O, Henderson DC, Macklin EA, et al. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebo-controlled pilot trial. J Clin Psychiatry 2009; 70:1674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/44\">",
"      Sevy S, Rosenthal MH, Alvir J, et al. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry 2005; 66:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/45\">",
"      Newport DJ, Calamaras MR, DeVane CL, et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J Psychiatry 2007; 164:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6793/abstract/46\">",
"      Croarkin PE, Emslie GJ, Mayes TL. Neuroleptic malignant syndrome associated with atypical antipsychotics in pediatric patients: a review of published cases. J Clin Psychiatry 2008; 69:1157.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14772 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-6AD27EA953-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_40_6793=[""].join("\n");
var outline_f6_40_6793=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H350566201\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20931793\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20931856\">",
"      INDICATIONS AND CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98146982\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98146995\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98147064\">",
"      Heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98147085\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H207140\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H207147\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H207154\">",
"      Pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20932047\">",
"      ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98147235\">",
"      Pre-treatment assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20931863\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98147514\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H207044\">",
"      - White blood count",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H207056\">",
"      - Cardiovascular",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20932063\">",
"      ADVERSE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20931954\">",
"      Agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20931961\">",
"      Myocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20931968\">",
"      Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20931975\">",
"      Weight gain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20931982\">",
"      Insulin resistance and diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20931989\">",
"      Seizures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20931996\">",
"      Excessive salivation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20932003\">",
"      Urinary incontinence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20932010\">",
"      Constipation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20932017\">",
"      Sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19303378\">",
"      Teratogenic and neonatal risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27026146\">",
"      Mortality risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3912828\">",
"      Movement disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H350566201\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14772\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14772|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?43/13/44243\" title=\"form 1\">",
"      Abnormal involuntary movement scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11226?source=related_link\">",
"      Bipolar disorder in adults: Teratogenic and postnatal risks of pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/4/31818?source=related_link\">",
"      Initial treatment of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/57/30616?source=related_link\">",
"      Management of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/47/18170?source=related_link\">",
"      Overview of neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2312?source=related_link\">",
"      Screening for diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/11/19642?source=related_link\">",
"      Status epilepticus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/8/34952?source=related_link\">",
"      Tardive dyskinesia: Prevention and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_40_6794="Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system";
var content_f6_40_6794=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/40/6794/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/40/6794/contributors\">",
"     David S Klimstra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/40/6794/contributors\">",
"     Zhaohai Yang, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/40/6794/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/40/6794/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/40/6794/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/40/6794/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/40/6794/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H440387060\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroendocrine cells are distributed widely throughout the body. Neuroendocrine neoplasms, defined as epithelial neoplasms with predominant neuroendocrine differentiation, can arise in most organs. While some clinical and pathologic features of these tumors are unique to the site of origin, other characteristics are shared, regardless of site.",
"   </p>",
"   <p>",
"    The classification and nomenclature of neuroendocrine neoplasms is complex and confusing, in part because most studies have focused on tumors arising in a specific organ system. Site-specific proposals for nomenclature and classification differ in terminology and in the criteria for histologic grading and staging, and this has led to morphologically similar neuroendocrine neoplasms being designated differently, depending on the site of origin. For now, there is no one single system of nomenclature, grading, or staging that is suitable for neuroendocrine neoplasms at all anatomic sites. However, features such as the proliferative rate of the tumor and the extent of local spread are shared by most classification systems. &nbsp;",
"   </p>",
"   <p>",
"    Neuroendocrine tumors (NETs) of the digestive system (gastroenteropancreatic NETs, tumors arising in the tubular gastrointestinal [GI] tract and the pancreas) are relatively rare. The annual incidence in the United States is about 3.65 per 100,000 population [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/1\">",
"     1",
"    </a>",
"    ]. The incidence has been rising over time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical characteristics of carcinoid tumors\", section on 'Epidemiology'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    The terminology of gastroenteropancreatic NETs has evolved over the past two decades to reflect a separation into two major categories:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Well-differentiated NETs, which show a solid, trabecular, gyriform, or glandular pattern, with fairly uniform nuclei, salt-and-pepper chromatin, and finely granular cytoplasm. These tumors were traditionally referred to as carcinoid and pancreatic neuroendocrine (islet cell) tumors. Although carcinoid tumors and pancreatic NETs may have similar characteristics on routine histologic evaluation, they have a different pathogenesis and biology. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=see_link&amp;anchor=H262522852#H262522852\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Classification and nomenclature'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Poorly differentiated neuroendocrine carcinomas, which are high-grade carcinomas that resemble small cell or large cell neuroendocrine carcinoma of the lung (",
"      <a class=\"graphic graphic_picture graphicRef74630 \" href=\"UTD.htm?26/10/26794\">",
"       picture 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H1176454#H1176454\">",
"       \"Pathology of lung malignancies\", section on 'Neuroendocrine tumors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Poorly differentiated neuroendocrine carcinomas are often associated with a rapid clinical course, while well-differentiated NETs generally have a much better prognosis, with an overall five-year survival of approximately 67 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/3\">",
"     3",
"    </a>",
"    ]. However, well differentiated NETs of the digestive tract are not a homogeneous group, but instead, display a spectrum of aggressiveness. Although most grow slowly and have an indolent course, up to 40 percent have already metastasized at the time of diagnosis, most commonly to the liver. Even in the presence of liver metastases, some patients may survive for many years. As a result of this relatively indolent natural history, well-differentiated NETs are often referred to as &ldquo;cancers in slow motion&rdquo;.",
"   </p>",
"   <p>",
"    For neuroendocrine neoplasms, morphology alone often cannot predict tumor behavior. Over the past two decades, various classification and grading schemes have been proposed for these tumors in an attempt to better define their clinical behavior. This topic review will cover pathology, classification, and histologic grading of NETs of the digestive tract, with an emphasis on well-differentiated tumors and the influence of proliferative rate. The pathology of NETs arising in the lungs is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H1176454#H1176454\">",
"     \"Pathology of lung malignancies\", section on 'Neuroendocrine tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440387068\">",
"    <span class=\"h1\">",
"     PATHOLOGY, TUMOR CLASSIFICATION, AND NOMENCLATURE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799304\">",
"    <span class=\"h2\">",
"     Morphology and immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protocols for the examination of specimens from patients with carcinoid tumors of the tubular gastrointestinal tract and pancreatic endocrine tumors are available from the College of American Pathologists [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On gross appearance, NETs of the tubular gastrointestinal tract are often well circumscribed round lesions in the submucosa or extending to the muscular layer, while pancreatic NETs may be either well circumscribed or infiltrative. The cut surface appears red to tan, reflecting the abundant microvasculature, or sometimes yellow because of high lipid content (",
"    <a class=\"graphic graphic_picture graphicRef74672 \" href=\"UTD.htm?39/19/40240\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef68174 \" href=\"UTD.htm?35/28/36292\">",
"     picture 3",
"    </a>",
"    ). Morphologically, well-differentiated NETs have characteristic &ldquo;organoid&rdquo; arrangements of the tumor cells, with",
"    <span class=\"nowrap\">",
"     solid/nesting,",
"    </span>",
"    trabecular, or gyriform patterns. The cells are relatively uniform, and they have round to oval nuclei, coarsely stippled chromatin, and finely granular cytoplasm. The cells produce abundant neurosecretory granules, as reflected in the strong and diffuse immunohistochemical expression of neuroendocrine markers such as synaptophysin and chromogranin. In addition, some tumors may secrete specific peptide hormones or bioamines such as insulin, glucagon, somatostatin, VIP (vasoactive intestinal peptide), serotonin, gastrin, etc., which may produce clinically evident hormonal syndromes. Generally, the histologic features of the tumor do not correlate with anatomic location or hormone production, but there are exceptions: amyloid deposition (insulin-associated peptide) often indicates an insulin-secreting pancreatic NET, and glandular architecture with abundant psammoma body formation is usually seen in duodenal or ampullary somatostatin-secreting NETs (",
"    <a class=\"graphic graphic_picture graphicRef75073 \" href=\"UTD.htm?15/35/15930\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Poorly differentiated neuroendocrine carcinomas less closely resemble non-neoplastic neuroendocrine cells, and have a more sheet-like or diffuse architecture, irregular nuclei, and less cytoplasmic granularity. Immunohistochemical expression of neuroendocrine markers is generally more limited. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H1176454#H1176454\">",
"     \"Pathology of lung malignancies\", section on 'Neuroendocrine tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799311\">",
"    <span class=\"h2\">",
"     Classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classification of gastroenteropancreatic NETs has evolved considerably, as evidenced by the transition in classification of tumors by the World Health Organization (WHO) over the last two decades (",
"    <a class=\"graphic graphic_table graphicRef74648 \" href=\"UTD.htm?12/13/12508\">",
"     table 1",
"    </a>",
"    ). Classification based upon morphology alone is not very useful, particularly for well-differentiated tumors, because histologic features do not accurately predict a benign or malignant clinical course. Although nuclear pleomorphism often correlates with differentiation (ie, the extent to which the neoplastic cells resemble their normal, nonneoplastic counterparts) and malignant behavior in other tumor types, it is of little use in NETs. Until recently, it was held that the only unequivocal evidence of malignancy was the presence of invasion or metastasis.",
"   </p>",
"   <p>",
"    Traditionally, gastroenteropancreatic NETs were referred to as carcinoid or pancreatic neuroendocrine (islet cell) tumors. The term carcinoid has been criticized because it does not convey the potential for malignant behavior that accompanies these neoplasms. Nevertheless, this term remains in widespread use, both in the official WHO classification of NETs of the lung and as a synonym for NETs arising in the tubular GI tract. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H20#H20\">",
"     \"Pathology of lung malignancies\", section on 'Non-small cell neuroendocrine tumors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=see_link&amp;anchor=H6#H6\">",
"     \"Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging\", section on 'WHO classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2474971\">",
"    <span class=\"h3\">",
"     Historical evolution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The key milestones that led to the modern classification system used for gastroenteropancreatic NETs are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 1907, Orberndorfer introduced the term &ldquo;carcinoid&rdquo; (carcinoma-like) to describe a type of morphologically distinct intestinal tumor with tight nests of small uniform cells [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 1963, Williams and Sandler proposed to classify carcinoid tumors into foregut (bronchus, thymus, esophagus, stomach, duodenum, upper jejunum, biliary tract, and pancreas), midgut (lower jejunum, ileum, appendix, cecum, and proximal colon), and hindgut (distal colon and rectum) tumors based upon their embryonic segments [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/8\">",
"       8",
"      </a>",
"      ]. This classification had limited value due to heterogeneous tumors in each category.",
"     </li>",
"     <li>",
"      In 1971, Soga and Tazawa classified NET based on histologic architecture into so-called type A, B, C, D, and mixed type [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/9\">",
"       9",
"      </a>",
"      ]. However, the pattern did not reliably predict the primary location of the tumor or prognosis.",
"     </li>",
"     <li>",
"      The 1980, WHO classification focused on various silver and other granule staining techniques to classify NETs into enterochromaffin (EC) cell carcinoid, gastrin cell carcinoid, and other carcinoids. It had little consideration of tumor grade or biologic behavior, nor did it predict patient outcome and thus now is obsolete [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 1995 proposal by Capella first introduced the idea of using the term neuroendocrine tumor (NET) instead of &ldquo;carcinoid&rdquo; or &ldquo;islet cell tumor&rdquo; [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/10\">",
"       10",
"      </a>",
"      ]. NETs were classified into four groups (I-IV), mainly based upon size and angioinvasion: benign, benign or low-grade malignant, low-grade malignant, and high-grade malignant. The prognostic value of this revised classification was subsequently validated [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/11\">",
"       11",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Other features were later shown to correlate with malignant behavior, including perineural and capsular invasion, high mitotic index, and tumor necrosis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/12\">",
"       12",
"      </a>",
"      ]. In 1997, it was suggested that pancreatic NETs",
"      <strong>",
"      </strong>",
"      could be separated into prognostically different groups based upon tumor size and mitotic activity [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Efforts to refine prognosis culminated in the WHO classification of NETs for the tubular GI tract in 2000 and the pancreas in 2004, which were essentially modified versions of the Capella classification [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/14\">",
"       14",
"      </a>",
"      ]. Based upon a combination of tumor size, vascular and perineural invasion, proliferative activity, local invasion, and lymph node and distant metastases, NETs were separated into well-differentiated neuroendocrine tumor with benign behavior, well-differentiated neuroendocrine tumor with uncertain behavior, well-differentiated neuroendocrine carcinoma, and poorly differentiated neuroendocrine carcinoma. &nbsp;",
"      <br/>",
"      <br/>",
"      The prognostic value of this system was subsequently validated [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/15-18\">",
"       15-18",
"      </a>",
"      ], but it was slow to gain acceptance in the United States due to its complexity and several shortcomings that emerged:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       2000/2004",
"      </span>",
"      WHO classifications used a hybrid of grading (the inherent biologic aggressiveness of the tumors as assessed by histologic features such as mitotic activity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Ki67 labeling index) and staging (disease extent as measured by tumor size, invasion and metastasis). Given that tumor grade and stage are considered separate parameters with independent prognostic significance, each should be assessed independently.",
"     </li>",
"     <li>",
"      There was no further prognostic stratification for metastatic NETs, despite the recognition that some cases continue to progress very slowly whereas others had a more rapidly progressive course, reflecting the influence of tumor grade even in advanced stages of the disease.",
"     </li>",
"     <li>",
"      Follow-up studies revealed that more than one-half of the resected NETs initially classified as having &ldquo;uncertain behavior&rdquo; eventually recurred, suggesting that most of these are best regarded as malignant.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2474956\">",
"    <span class=\"h3\">",
"     2010 WHO classification",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2006 and 2007, the European Neuroendocrine Tumour Society (ENETS) proposed a staging scheme, similar to most other types of epithelial neoplasms, for NETs of the digestive tract that was accompanied by a histologic grading system that could be applied to all stages of NETs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. This grading proposal was later endorsed by the American Joint Committee on Cancer (AJCC) (",
"    <a class=\"graphic graphic_table graphicRef53740 \" href=\"UTD.htm?27/28/28107\">",
"     table 2",
"    </a>",
"    ), although they modified the ENETS staging proposal [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13525387\">",
"     'Staging system'",
"    </a>",
"    below.)",
"    <br/>",
"    <br/>",
"    The 2010 WHO classification of tumors of the GI tract, liver, and pancreas also endorsed the ENETS grading scheme for NETs of the digestive tract, separating well-differentiated tumors into low-grade (G1) and intermediate grade (G2) categories (",
"    <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. All poorly differentiated neuroendocrine tumors are high-grade (G3) neuroendocrine carcinomas according to this classification scheme.",
"   </p>",
"   <p>",
"    Although some previous proposals for grading pancreatic NETs included the presence of necrosis (which paralleled the grading system used for bronchial carcinoid tumors) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], the",
"    <span class=\"nowrap\">",
"     ENETS/WHO",
"    </span>",
"    grade for NETs is based solely on proliferative rate, using mitotic activity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Ki67 labeling index. The WHO guidelines specify that mitotic counting is to be performed on 40 to 50 high power fields, and 2000 cells should be counted to determine the Ki67 index. The regions with the highest rates (&ldquo;hot spots&rdquo;) should be counted, and if there is disparity between the mitotic rate and the Ki67 index, the higher grade should be assigned. (See",
"    <a class=\"local\" href=\"#H799582\">",
"     'Technical aspects'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H440387097\">",
"     'Intratumoral heterogeneity'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13525387\">",
"    <span class=\"h4\">",
"     Staging system",
"    </span>",
"    &nbsp;&mdash;&nbsp;The WHO also endorsed staging NETs using the specified TNM-based system. The most recent 7",
"    <sup>",
"     th",
"    </sup>",
"    edition of the AJCC staging manual, which reflects a modification of proposal by ENETS [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/19\">",
"     19",
"    </a>",
"    ], includes separate TNM staging systems for NETs of the appendix (",
"    <a class=\"graphic graphic_table graphicRef50547 \" href=\"UTD.htm?4/18/4397\">",
"     table 4",
"    </a>",
"    ), pancreas (",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"UTD.htm?42/32/43532\">",
"     table 5",
"    </a>",
"    ), stomach (",
"    <a class=\"graphic graphic_table graphicRef65045 \" href=\"UTD.htm?40/55/41852\">",
"     table 6",
"    </a>",
"    ), small",
"    <span class=\"nowrap\">",
"     bowel/ampulla",
"    </span>",
"    of Vater (",
"    <a class=\"graphic graphic_table graphicRef58532 \" href=\"UTD.htm?41/15/42236\">",
"     table 7",
"    </a>",
"    ), and colorectal primary sites (",
"    <a class=\"graphic graphic_table graphicRef53191 \" href=\"UTD.htm?2/22/2413\">",
"     table 8",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=see_link&amp;anchor=H4#H4\">",
"     \"Cancer of the appendix and pseudomyxoma peritonei\", section on 'Staging and prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link&amp;anchor=H10#H10\">",
"     \"Insulinoma\", section on 'Staging system'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\", section on 'Rectum'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link&amp;anchor=H432448#H432448\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\", section on 'Colon'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\", section on 'Stomach'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link&amp;anchor=H4#H4\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\", section on 'Small intestine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Notable differences between the ENETS proposal and AJCC manual include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The ENETS proposal stages poorly differentiated neuroendocrine carcinoma in the same way as well differentiated NETs; while AJCC stages poorly differentiated neuroendocrine carcinomas as adenocarcinomas.",
"     </li>",
"     <li>",
"      AJCC applies the adenocarcinoma staging scheme to all pancreatic neoplasms (including both well differentiated NETs and poorly differentiated neuroendocrine carcinoma). Furthermore, the T-stage definitions differed between the AJCC and ENETS systems. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear which staging system provides better separation of the prognostically different groups; at least one analysis using a large international cohort study concluded that for pancreatic NETs, the ENETS staging system provided superior prognostic stratification [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/27\">",
"     27",
"    </a>",
"    ]. At least in the United States, the majority of pathologists must use the AJCC system if the department has accreditation from the College of American Pathologists.",
"   </p>",
"   <p>",
"    <br/>",
"    The prognostic validity of both TNM stage and proliferative rate using this new system in luminal GI tract and pancreatic NETs is supported by several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/28-36\">",
"     28-36",
"    </a>",
"    ]. As an example, in one series of 425 patients with a pancreatic NET, five-year survival rates for low, intermediate, and high-grade tumors were 75, 62, and 7 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/34\">",
"     34",
"    </a>",
"    ]. Using the AJCC classification, five-year overall survival rates for stage I, II, III, and IV tumors were 92, 84, 81, and 57 percent, respectively.",
"   </p>",
"   <p>",
"    However, others note no significant difference in outcomes between stage I and II midgut (jejunal and ileocecal) carcinoids (five-year overall survival 100 percent for both), and heterogeneous outcomes in patients with stage IIIB (node-positive) disease depending on whether disease was resected (five-year overall survival 95 percent) or unresectable (five-year overall survival 78 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/36\">",
"     36",
"    </a>",
"    ]. Neither the ENETS nor the AJCC staging systems acknowledge a distinction between resected and microscopically involved versus large and unresectable mesenteric lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=see_link&amp;anchor=H19140597#H19140597\">",
"     \"Treatment and surveillance of non-metastatic carcinoid tumors\", section on 'Stage and site of origin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    NETs of unknown primary, especially the well differentiated ones, often present initially with liver metastases, and most of these represent gastroenteropancreatic NETs. Thus the new uniform grading scheme also applies to this category unless a different primary site is found. NETs of unknown primary are, by definition, metastatic disease and therefore considered stage IV in all TNM staging systems. For this reason, the histologic grade is particularly important and may be the only prognostic parameter available for this group of tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=see_link\">",
"     \"Neuroendocrine cancer of unknown primary site\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799428\">",
"    <span class=\"h3\">",
"     Functionality and nomenclature",
"    </span>",
"    &nbsp;&mdash;&nbsp;Functionality also impacts on nomenclature. Functioning NETs are defined based upon the presence of clinical symptoms due to excess hormone secretion by the tumor. Functioning (hormone-secreting) pancreatic NETs are classified according to the predominant hormone they secrete and the resulting clinical syndrome (eg, insulinoma, gastrinoma, glucagonoma, VIPoma, somatostatinoma) (",
"    <a class=\"graphic graphic_table graphicRef69622 \" href=\"UTD.htm?33/6/33900\">",
"     table 9",
"    </a>",
"    ). Immunohistochemical staining is not a defining criterion for tumor classification. For example, if a tumor stains for gastrin but does not produce symptoms of the Zollinger-Ellison syndrome, it should not be considered a gastrinoma; however, gastrin-secreting NET would be an appropriate term. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=see_link\">",
"     \"Insulinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31640?source=see_link\">",
"     \"Glucagonoma and the glucagonoma syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=see_link\">",
"     \"The VIPoma syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3623?source=see_link\">",
"     \"Somatostatinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although functionality may impact prognosis (eg, insulinomas are generally indolent tumors), the biologic behavior of most functioning NETs is defined by the grade and stage of the tumor. Thus, the pathologic diagnosis of a functioning pancreatic NET should be the same as for a nonfunctioning NET, with the descriptive functional designation appended to the diagnosis where there is knowledge of a clinical syndrome. Carcinoid tumors are classified similarly whether they produce symptoms of the carcinoid syndrome or not. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=see_link\">",
"     \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800434\">",
"    <span class=\"h1\">",
"     ISSUES RELATED TO ASSESSING GRADE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 WHO classification of NETs relies extensively on proliferative rate to separate low, intermediate, and high-grade tumors (",
"    <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"     table 3",
"    </a>",
"    ). Proliferate rate can be assessed using either mitotic counts or Ki67 labeling index.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440387075\">",
"    <span class=\"h2\">",
"     Assessment of mitotic activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitotic activity is an accepted measure of the inherent proliferative potential of NETs, but there is no general agreement as to the cutoff values that best separate different grades, especially among NETs of different anatomic sites (",
"    <a class=\"graphic graphic_table graphicRef54667 \" href=\"UTD.htm?24/37/25181\">",
"     table 10",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a survival analysis of 200 pulmonary NETs, mitotic count was the only independent predictor of prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. In that study, the cutoff point that best distinguished low grade (carcinoid) from intermediate grade (atypical carcinoid) tumors was 2 mitoses per 10 high-power fields",
"      <span class=\"nowrap\">",
"       (2/10",
"      </span>",
"      HPF). In this system, necrosis was also considered in the assignment of intermediate grade. High-grade tumors were defined as having a mitotic count",
"      <span class=\"nowrap\">",
"       &gt;10/10",
"      </span>",
"      HPF.",
"     </li>",
"     <li>",
"      In a study of thymic NETs, mitotic count was also found to correlate with survival, but the best cutoff value to distinguish low-grade and intermediate-grade was",
"      <span class=\"nowrap\">",
"       3/10",
"      </span>",
"      HPF [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/39\">",
"       39",
"      </a>",
"      ]. Despite this finding, the WHO classification for thymic carcinoids uses a cutoff of",
"      <span class=\"nowrap\">",
"       &lt;2/10",
"      </span>",
"      HPF to distinguish a low-grade thymic carcinoid tumor from an intermediate grade atypical thymic carcinoid. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=see_link&amp;anchor=H14#H14\">",
"       \"Pathology of mediastinal tumors\", section on 'Thymic neuroendocrine tumors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21962?source=see_link&amp;anchor=H703971797#H703971797\">",
"       \"Thymic neuroendocrine (carcinoid) tumors\", section on 'Pathology and classification'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The use of a",
"      <span class=\"nowrap\">",
"       2/10",
"      </span>",
"      HPF cutoff point to stratify prognosis among well-differentiated pancreatic NETs was supported by subsequent studies [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/12,25\">",
"       12,25",
"      </a>",
"      ], and most groups (including the new 2010 WHO classification system for NETs) use",
"      <span class=\"nowrap\">",
"       2/10",
"      </span>",
"      HPF (2 mm",
"      <sup>",
"       2",
"      </sup>",
"      , see below) (",
"      <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/19-23\">",
"       19-23",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The cutoff to define poorly differentiated gastroenteropancreatic NETs is",
"      <span class=\"nowrap\">",
"       20/10",
"      </span>",
"      HPF, which differs from the cutoff used for high-grade pulmonary and thymic NETs",
"      <span class=\"nowrap\">",
"       (10/10",
"      </span>",
"      HPF). One exception is that Hochwald et al used",
"      <span class=\"nowrap\">",
"       2/50",
"      </span>",
"      HPF as the cutoff for pancreatic NETs, which was endorsed in the AFIP Fascicle for pancreatic tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/13,24\">",
"       13,24",
"      </a>",
"      ]. Based on the 2010 WHO classification, the cutoff to define poorly differentiated gastroenteropancreatic neuroendocrine carcinoma is now",
"      <span class=\"nowrap\">",
"       20/10",
"      </span>",
"      HPF, which differs from the cutoff used in",
"      <span class=\"nowrap\">",
"       2000/2004",
"      </span>",
"      WHO classifications as well as that for high-grade pulmonary and thymic neuroendocrine carcinoma",
"      <span class=\"nowrap\">",
"       (10/10",
"      </span>",
"      HPF). (See",
"      <a class=\"local\" href=\"#H440387118\">",
"       'Poorly differentiated neuroendocrine carcinoma'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799582\">",
"    <span class=\"h3\">",
"     Technical aspects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all grading schemes that rely on mitotic count, the difference between low and intermediate grade is subtle and may hinge on only one mitotic figure per 10 HPF; thus, it is very important to count the mitoses accurately. It is recommended that only clear-cut mitotic figures be counted, excluding degenerating dark-stained nuclei and apoptotic bodies.",
"   </p>",
"   <p>",
"    In addition, the size of the microscopic field matters tremendously; the size of 10 HPF is set to 2 mm",
"    <sup>",
"     2",
"    </sup>",
"    for standardization. For the microscopes used in earlier studies, the size of 10 HPF (using a 40x objective) roughly equals 2 mm",
"    <sup>",
"     2",
"    </sup>",
"    ; however, the size of the fields has not been standardized between different brands of microscopes, a fact that has not been considered in some studies. As illustrated in the original study of pulmonary carcinoid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/38\">",
"     38",
"    </a>",
"    ], the 40x field of the Olympus BX40 microscope (which is commonly used by pathologists) with a standard",
"    <span class=\"nowrap\">",
"     10X/22",
"    </span>",
"    eyepiece has an area of 0.24 mm",
"    <sup>",
"     2",
"    </sup>",
"    , thus only 8.3 HPFs are needed to view a 2 mm",
"    <sup>",
"     2",
"    </sup>",
"    area. If one counts 10 HPF with this microscope, one will actually view 2.4 mm",
"    <sup>",
"     2",
"    </sup>",
"    , 20 percent more than intended, thus potentially overestimating the grade.",
"   </p>",
"   <p>",
"    Finally, although NET cells are generally small and uniform with round nuclei and moderate cytoplasm, there is great variability in cell size between tumors. Some tumor cells have more abundant cytoplasm, and in tumors with ribbon-like or glandular patterns, there is more tumor-free space in a microscopic field (",
"    <a class=\"graphic graphic_picture graphicRef75073 \" href=\"UTD.htm?15/35/15930\">",
"     picture 4",
"    </a>",
"    ). In addition, stromal fibrosis is common in NETs and can be extensive, limiting the proportion of the tumor that contains neoplastic cells. For these reasons, simply counting 10 HPF or 2 mm",
"    <sup>",
"     2",
"    </sup>",
"    does not mean we are evaluating the same number of tumor cells.",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     ENETS/WHO",
"    </span>",
"    recommend counting 40 to 50 HPFs to obtain an average count; however, this does not completely eliminate the above problems [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/19,20,23\">",
"     19,20,23",
"    </a>",
"    ]. It would be more accurate to count a certain number of cells as for Ki67 labeling index (see below) and to express the mitotic rate as a percentage of neoplastic cells. This is tedious and thus far no proposals for this method have been advanced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440387082\">",
"    <span class=\"h2\">",
"     Assessment of Ki67 labeling index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Ki67 protein is a large nuclear protein (395 kDa) that is closely associated with the nucleolus and heterochromatin. Ki67 is expressed in G1, S, G2 and M phases, with a peak level during mitosis. The exact function of Ki67 is unknown, but it appears to be involved in cell cycle regulation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    organization of the nucleolus; removal of Ki67 prevents cell proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A lack of understanding of molecular function has not precluded widespread use of Ki67 as a prognostic marker for NETs. In an early study using semiquantitative assessment, increased Ki67 staining appeared to correlate with worse prognosis in NETs of the digestive tract [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/42\">",
"     42",
"    </a>",
"    ]. However, the original Ki67 antibody only worked on fresh and frozen tissue, limiting its use. More recent studies have utilized the monoclonal MIB-1 antibody, which works well on formalin-fixed, paraffin-embedded tissue.",
"   </p>",
"   <p>",
"    As with mitotic index, determining optimal cutoffs has plagued efforts to standardize grading using Ki67 (",
"    <a class=\"graphic graphic_table graphicRef54667 \" href=\"UTD.htm?24/37/25181\">",
"     table 10",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In some studies, 5 percent represents the best cutoff to predict survival in well-differentiated pancreatic NETs [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/33,43\">",
"       33,43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Others have found that a cutoff of 2 percent was a sensitive and specific marker for prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ki67 labeling index is a continuous variable, and different groups have chosen 2.5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/44\">",
"       44",
"      </a>",
"      ] or 2.6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/45\">",
"       45",
"      </a>",
"      ] for their studies.",
"     </li>",
"     <li>",
"      The use of a 3 percent cutoff point to stratify prognosis among well-differentiated pancreatic NETs is supported by subsequent studies [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/28-32\">",
"       28-32",
"      </a>",
"      ], and most groups, including the ENETS and WHO, use a uniform cutoff of &lt;3 percent to define low grade (G1) from intermediate grade NETs of the digestive tract (",
"      <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"       table 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/19,20,23\">",
"       19,20,23",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Through the mid 2000s, the proliferative rate that was used to define poorly-differentiated (high grade) neuroendocrine carcinomas was 10 percent, and this was the rate used in the 2004 WHO classification and in several studies [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/14,46\">",
"       14,46",
"      </a>",
"      ]. In 2006 and 2007, the ENETS proposed to raise this rate to 20 percent, which was endorsed by the WHO and AJCC [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/19-21,23\">",
"       19-21,23",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, the optimal cutoff value for the Ki67 labeling index to distinguish low, intermediate, and high-grade gastroenteropancreatic NETs has not been established. However, the ENETS, AJCC, and the 2010 WHO classification include a uniform Ki67 labeling cutoff of &lt;3 percent to define low grade (G1), 3 to 20 percent for intermediate grade (G2), and &gt;20 percent for high-grade (G3) NETs (",
"    <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. Assignment of grade based upon these Ki67 cutoffs has been shown to correlate with patient survival independent of tumor stage in both primary and metastatic gastroenteropancreatic NETs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/28-32\">",
"     28-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     WHO/ENETS",
"    </span>",
"    guidelines further specify that 2000 cells should be counted to determine the Ki67 index [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/23\">",
"     23",
"    </a>",
"    ]. Cells should be chosen in regions with the highest rates (&ldquo;hot spots&rdquo;).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800183\">",
"    <span class=\"h3\">",
"     Technical aspects",
"    </span>",
"    &nbsp;&mdash;&nbsp;To establish the percent of positive cells (the Ki67 labeling index), manual counting of a certain number of nuclei (eg, 2000 as recommended by",
"    <span class=\"nowrap\">",
"     WHO/ENETS,",
"    </span>",
"    although an acceptable grade may be obtained with as few as 500 cells) is used. This method is considered overly burdensome and not practical [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/47\">",
"     47",
"    </a>",
"    ]. Alternatively, some pathologists choose to estimate the labeling index by scanning the slide or &ldquo;eyeballing&rdquo;. Eyeballing may be sufficient to separate low to intermediate grade from frankly high-grade tumors (ie, Ki67 of 1 to 20 versus &gt;50 percent) but this approach is often criticized due to a lack of precision and reproducibility [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When either manual counting or &ldquo;eyeballing&rdquo; is used for research studies, issues of intraobserver",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interobserver variability necessitate some sort of statistical confirmation (eg, the Bland-Altman approach [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/48\">",
"     48",
"    </a>",
"    ]) to ensure that intraobserver variability is within an acceptable range. Digital image analysis has been validated for the assessment of nuclear markers with much less variability than manual counting or &ldquo;eyeballing&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/32,49-51\">",
"     32,49-51",
"    </a>",
"    ], thus avoiding the need for complicated statistical analyses for reproducibility. Particularly because of the anticipated wide utilization of digital slides in the near future, image analysis can be easily incorporated into the analytic software and a Ki67 labeling index is thus generated automatically. However, digital image analysis also carries its own drawbacks. The inclusion of areas with necrosis, hemorrhage, fibrosis, non-neoplastic tissue or high background labeling in the analysis may lead to misleading results. For instance, non-neoplastic lymphocytes within a tumor often label for Ki67, and measuring a region with significant lymphocytes can grossly overestimate the Ki67 index. This problem may be mitigated by human intervention, software improvement, and laboratory standardization; however, these issues will increase the time needed to perform accurate digital quantification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H800190\">",
"    <span class=\"h2\">",
"     Choice of method",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best method (mitotic counting versus Ki67 labeling index) to establish the proliferative rate is not established. The",
"    <span class=\"nowrap\">",
"     ENETS/WHO",
"    </span>",
"    classification system provides criteria for BOTH mitotic rate counting and Ki67 labeling as an assessment of proliferative rate, without a preference for one method over the other [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/23\">",
"     23",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Although mitotic counting can be performed without immunohistochemical staining, the Ki67 labeling index offers several advantages:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Ki67 labeling index is based on the percentage of positive cells, which is not affected by the size of the microscopic field or the number of neoplastic cells in a given area of the tumor.",
"     </li>",
"     <li>",
"      In most tumors, there are many more Ki67-labeled cells than there are cells in mitosis. In a limited specimen such as liver biopsy, GI biopsy, or fine needle aspiration of the pancreas, there may be only a few high power fields available, much less than the 40 to 50 HPFs required for accurate mitotic counting, and an accurate determination of mitotic rate is difficult in those cases. However, 500 to 2000 cells are generally present even in those limited specimens, from which a Ki67 index can be comfortably obtained.",
"     </li>",
"     <li>",
"      With the advent of the digital era, the Ki67 labeling index has the potential of at least partial automation, thus eliminating the tedious work of counting a certain number of cells or HPFs. (See",
"      <a class=\"local\" href=\"#H800183\">",
"       'Technical aspects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the advantages of using Ki67 to define the proliferative rate, this is not yet in widespread use in the United States, and a consensus statement covering pathology reporting of NETs suggested that Ki67 staining is not needed when there is sufficient tumor to perform an accurate mitotic count [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/47\">",
"     47",
"    </a>",
"    ]. A common practice is to use mitotic counting for grading in resection specimens and to use the Ki67 labeling index for more limited material.",
"   </p>",
"   <p>",
"    The Ki67 labeling index generally correlates with the mitotic count [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/31,44\">",
"     31,44",
"    </a>",
"    ]. The Ki67 protein has a short half-life, and its amount and localization changes with the cell cycle, which may explain the rare discrepancies observed by some authors. In cases with discordance between these two measures of proliferation, the WHO classification recommends using the higher grade [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/23\">",
"     23",
"    </a>",
"    ], although the validity of this approach has not been confirmed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440387097\">",
"    <span class=\"h2\">",
"     Intratumoral heterogeneity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Heterogeneity of proliferative rate within a tumor (or among different sites of disease if metastases are present) is a common finding in NETs. Even on a single slide, there may be great variability in terms of mitotic count and Ki67 labeling index (",
"    <a class=\"graphic graphic_picture graphicRef67423 \" href=\"UTD.htm?32/54/33642\">",
"     picture 5",
"    </a>",
"    ). Within the",
"    <span class=\"nowrap\">",
"     ENETS/WHO",
"    </span>",
"    classification system, it is recommended that at least 40 high power fields should be counted for mitoses and that areas of highest labeling (&ldquo;hot spots&rdquo;) should be used to determine the Ki67 labeling index [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If Ki67 staining is performed on a large specimen such as a resection, it is relatively simple to scan the tumor at low power to identify the hot spots of greatest labeling. However, within a limited specimen (eg, core needle biopsy), the Ki67 index may not be representative. Furthermore, there are few data addressing whether the proliferative rate within hot spot areas more accurately predicts prognosis than, for example, the average proliferative rate in the entire tumor.",
"   </p>",
"   <p>",
"    This issue has been addressed in at least two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study that used tissue microarrays to assess prognostic markers in biopsies from pancreatic NET liver metastases, there was good correlation between the Ki67 labeling indices in two random cores taken from a single metastasis [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/48\">",
"       48",
"      </a>",
"      ]. However, in 16 of 29 cases the difference between samples was sufficient to change the grade (G1 versus G2 or even G3).",
"     </li>",
"     <li>",
"      Similarly, in an analysis of Ki67 labeling indices in simulated biopsies of metastatic well-differentiated NETs, nearly one-half of the tumors showed intratumoral heterogeneity that was sufficient to change the grade from G1 to G2 (",
"      <a class=\"graphic graphic_table graphicRef56255 \" href=\"UTD.htm?38/18/39211\">",
"       table 11",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/32\">",
"       32",
"      </a>",
"      ]. Histologic grade based upon either the average or highest Ki67 index demonstrated a statistically significant correlation with patient survival (",
"      <a class=\"graphic graphic_figure graphicRef80839 \" href=\"UTD.htm?41/46/42734\">",
"       figure 1",
"      </a>",
"      ). However, for overall survival, the grade according to the highest Ki67 index resulted in better separation of the two prognostically different groups than did grade as assessed using the average Ki67 index.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data support counting &ldquo;hot spots&rdquo; to assess Ki67 index in heterogeneous tumors. In such cases, a grade of G1 based upon a small, randomly directed biopsy may not represent the true grade of the tumor. In order to better predict patient outcome, multiple biopsies would be needed, although the optimal number has not been determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440387111\">",
"    <span class=\"h2\">",
"     Other parameters and markers for histological grading",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some prognostic parameters used in the Capella and earlier WHO classifications such as tumor size and the presence of metastasis are now regarded as part of the staging parameters in the AJCC staging system and new WHO classification [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/21,23\">",
"     21,23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H799311\">",
"     'Classification'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Tumor necrosis is one of the criteria for intermediate grade in the WHO classification of lung [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/37\">",
"     37",
"    </a>",
"    ] and thymic carcinoids [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/39\">",
"     39",
"    </a>",
"    ], and it was used in the Hochwald and AFIP classifications of pancreatic NETs (",
"    <a class=\"graphic graphic_table graphicRef54667 \" href=\"UTD.htm?24/37/25181\">",
"     table 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. However, necrosis is not a component of the most recent",
"    <span class=\"nowrap\">",
"     ENETS/WHO",
"    </span>",
"    classification for NETs of the digestive system [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/23\">",
"     23",
"    </a>",
"    ]. Similarly, lymphovascular and perineural invasion should also be recorded as prognostic factors but are not part of the grading criteria. Historically, immunohistochemical staining for PCNA (proliferating cell nuclear antigen) was considered an alternative marker of proliferative activity; however, it fell out of favor due to a lack of reliability [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several other newer markers have been reported to have prognostic value in NETs. CK19 (cytokeratin-19) is a marker of pancreatic ductal epithelium but also transiently expressed in islet cells. Its expression has been shown to correlate with worse survival in pancreatic NETs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/52\">",
"     52",
"    </a>",
"    ]. A classification scheme based upon expression of CK19 and CD117 (KIT) has been proposed, with CK19+ CD117+ pancreatic NETs having the shortest survival [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/53\">",
"     53",
"    </a>",
"    ]. Those markers may be useful in primary NETs, but they do not appear to have any prognostic significance in metastatic disease, unlike the Ki67 labeling index [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/31,32\">",
"     31,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The potential prognostic significance of other markers such as p27",
"    <sup>",
"     Kip1",
"    </sup>",
"    , CD99, and PAX8 is controversial even in primary tumors. The fact that some of the putative markers are also lineage-specific may have limited their value as a general prognostic marker for NETs. To date, none of these prognostic markers has achieved widespread use, and none are currently proposed as a basis for treatment stratification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440387118\">",
"    <span class=\"h1\">",
"     POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poorly differentiated neuroendocrine carcinomas are high-grade (G3) neuroendocrine carcinomas in the ENETS and 2010 WHO classifications (",
"    <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/23\">",
"     23",
"    </a>",
"    ]. While these tumors are included in many published studies of neuroendocrine tumors of the digestive system, they appear to represent a distinct group, with clinical behavior similar to that of small cell carcinoma or large cell neuroendocrine carcinoma of the lung, which is far worse than that of well-differentiated NETs. As a general rule, high-grade neuroendocrine carcinomas are treated with platinum based regimens, according to small cell carcinoma guidelines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link&amp;anchor=H12#H12\">",
"     \"Pathobiology and staging of small cell carcinoma of the lung\", section on 'Prognostic factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=see_link&amp;anchor=H190949019#H190949019\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion\", section on 'Poorly differentiated tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For poorly differentiated neuroendocrine carcinomas, the morphologic features often suggest the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/54\">",
"     54",
"    </a>",
"    ]. The proliferative rate of most cases is well in excess of the cutoffs proposed to distinguish them from well-differentiated NETs (&gt;20 percent Ki67 labeling index,",
"    <span class=\"nowrap\">",
"     &gt;20/10",
"    </span>",
"    HPF mitotic rate) (",
"    <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"     table 3",
"    </a>",
"    ). Even without in depth assessment, the high mitotic rate and Ki67 labeling index are usually readily apparent (",
"    <a class=\"graphic graphic_picture graphicRef75073 \" href=\"UTD.htm?15/35/15930\">",
"     picture 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Transformation from well-differentiated NETs into poorly differentiated carcinoma has only rarely been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?6/40/6794/abstract/55\">",
"     55",
"    </a>",
"    ]. Some tumors show features of well-differentiated NETs in some regions, including a low proliferative rate, but in other regions show a much higher proliferative rate along with more atypical cytologic features. Whether these tumors should be classified with the poorly differentiated neuroendocrine carcinomas (when the current WHO grading criteria are strictly followed) or as a more aggressive form of well-differentiated NET has yet to be established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H440387125\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuroendocrine tumors (NETs), which are defined as epithelial neoplasms with predominant neuroendocrine differentiation, arise throughout the body. The terminology of NETs arising in the digestive tract (gastroenteropancreatic NETs) has evolved over the past two decades to reflect a separation into two major categories (see",
"      <a class=\"local\" href=\"#H440387060\">",
"       'Introduction'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Well-differentiated NETs, which show a solid, trabecular, gyriform, or glandular pattern, with fairly uniform nuclei, salt-and-pepper chromatin, and finely granular cytoplasm.",
"     </li>",
"     <li>",
"      Poorly differentiated neuroendocrine carcinomas, which are high-grade carcinomas that resemble small cell carcinoma or large cell neuroendocrine carcinoma of the lung. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=see_link&amp;anchor=H1176454#H1176454\">",
"       \"Pathology of lung malignancies\", section on 'Neuroendocrine tumors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Poorly differentiated neuroendocrine carcinomas are often associated with a rapid clinical course, while well-differentiated NETs of the digestive system, generally have a much better prognosis. However, well-differentiated tumors are not a homogeneous group and there is a spectrum of aggressiveness. The biologic behavior of well-differentiated NETs cannot be predicted based on morphology alone. (See",
"      <a class=\"local\" href=\"#H799311\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Proliferative rate, as assessed by mitotic count",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      Ki67 labeling index, is of prognostic significance in well-differentiated NETs, independent of tumor stage. A grading scheme endorsed by the World Health Organization (WHO) for NETs of the digestive system classifies well-differentiated NETs into 2 categories based on the proliferative rate: low (G1) and intermediate grades (G2) (",
"      <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H799311\">",
"       'Classification'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The best cutoff to separate low-grade (G1) from intermediate-grade (G2) tumors is not established. The 2010 WHO classification uses 2 mitoses per 10 HPF,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      &gt;3 percent Ki67 staining as the cutoff values. (See",
"      <a class=\"local\" href=\"#H440387075\">",
"       'Assessment of mitotic activity'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H440387082\">",
"       'Assessment of Ki67 labeling index'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although patients with low-grade and intermediate-grade NETs of the digestive system are treated similarly at present, as new treatment modalities become available, it is likely that the histologic grade of a well-differentiated NET will affect the selection of appropriate treatment.",
"     </li>",
"     <li>",
"      Poorly differentiated neuroendocrine carcinomas are defined as high-grade (G3) neuroendocrine carcinoma in the 2010 WHO classifications (",
"      <a class=\"graphic graphic_table graphicRef60365 \" href=\"UTD.htm?17/14/17644\">",
"       table 3",
"      </a>",
"      ). While they are included in many published series of patients with NETs of the digestive tract, the prognosis is far worse than that of well-differentiated NETs, and they are more closely related to that of small cell carcinoma and large cell neuroendocrine carcinoma of the lung. They are treated similarly, with platinum-based chemotherapy. (See",
"      <a class=\"local\" href=\"#H440387118\">",
"       'Poorly differentiated neuroendocrine carcinoma'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=see_link&amp;anchor=H12#H12\">",
"       \"Pathobiology and staging of small cell carcinoma of the lung\", section on 'Prognostic factors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/1\">",
"      Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011; 40:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/2\">",
"      Gustafsson BI, Kidd M, Chan A, et al. Bronchopulmonary neuroendocrine tumors. Cancer 2008; 113:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/3\">",
"      Ramage JK, Davies AH, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005; 54 Suppl 4:iv1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/4\">",
"      Washington MK, Tang LH, Berlin J, et al. Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the small intestine and ampulla. Arch Pathol Lab Med 2010; 134:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/5\">",
"      Washington MK, Tang LH, Berlin J, et al. Protocol for the examination of specimens from patients with neuroendocrine tumors (carcinoid tumors) of the colon and rectum. Arch Pathol Lab Med 2010; 134:176.",
"     </a>",
"    </li>",
"    <li>",
"     College of American Pathologists protocol for examination of specimens from patients with carcinoma of the endocrine pancreas available online at file://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2009/PancreasEndo_09protocol.pdf (Accessed on August 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/7\">",
"      Kl&ouml;ppel G. Oberndorfer and his successors: from carcinoid to neuroendocrine carcinoma. Endocr Pathol 2007; 18:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/8\">",
"      WILLIAMS ED, SANDLER M. The classification of carcinoid tum ours. Lancet 1963; 1:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/9\">",
"      Soga J, Tazawa K. Pathologic analysis of carcinoids. Histologic reevaluation of 62 cases. Cancer 1971; 28:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/10\">",
"      Capella C, Heitz PU, H&ouml;fler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995; 425:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/11\">",
"      Heymann MF, Joubert M, Nemeth J, et al. Prognostic and immunohistochemical validation of the capella classification of pancreatic neuroendocrine tumours: an analysis of 82 sporadic cases. Histopathology 2000; 36:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/12\">",
"      La Rosa S, Sessa F, Capella C, et al. Prognostic criteria in nonfunctioning pancreatic endocrine tumours. Virchows Arch 1996; 429:323.",
"     </a>",
"    </li>",
"    <li>",
"     Solcia E, Capella C, Kloeppel G. Tumors of the pancreas. In: Atlas of tumor pathology, Rosai J, Sobin LH (Eds), AFIP, Washington, DC 1997. p.262.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/14\">",
"      Kl&ouml;ppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004; 1014:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/15\">",
"      Schindl M, Kaczirek K, Kaserer K, Niederle B. Is the new classification of neuroendocrine pancreatic tumors of clinical help? World J Surg 2000; 24:1312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/16\">",
"      Ferrone CR, Tang LH, Tomlinson J, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol 2007; 25:5609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/17\">",
"      Ekeblad S, Skogseid B, Dunder K, et al. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008; 14:7798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/18\">",
"      Formica V, Wotherspoon A, Cunningham D, et al. The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. Br J Cancer 2007; 96:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/19\">",
"      Rindi G, Kl&ouml;ppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/20\">",
"      Rindi G, Kl&ouml;ppel G, Couvelard A, et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007; 451:757.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/22\">",
"      Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39:707.",
"     </a>",
"    </li>",
"    <li>",
"     Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System, 4th ed, Bosman TF, Carneiro F, Hruban RH, Theise ND (Eds), International Agency for Research on cancer (IARC), Lyon 2010. p.13.",
"    </li>",
"    <li>",
"     Hruban RH, Pitman MB, Klimstra DS. Tumors of the pancreas, ARP/AFIP, Washington, DC 2007. p.422.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/25\">",
"      Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002; 20:2633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/26\">",
"      Cho CS, Labow DM, Tang L, et al. Histologic grade is correlated with outcome after resection of hepatic neuroendocrine neoplasms. Cancer 2008; 113:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/27\">",
"      Rindi G, Falconi M, Klersy C, et al. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 2012; 104:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/28\">",
"      Jann H, Roll S, Couvelard A, et al. Neuroendocrine tumors of midgut and hindgut origin: tumor-node-metastasis classification determines clinical outcome. Cancer 2011; 117:3332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/29\">",
"      La Rosa S, Inzani F, Vanoli A, et al. Histologic characterization and improved prognostic evaluation of 209 gastric neuroendocrine neoplasms. Hum Pathol 2011; 42:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/30\">",
"      Pape UF, Jann H, M&uuml;ller-Nordhorn J, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008; 113:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/31\">",
"      Strosberg J, Nasir A, Coppola D, et al. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol 2009; 40:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/32\">",
"      Yang Z, Tang LH, Klimstra DS. Effect of tumor heterogeneity on the assessment of Ki67 labeling index in well-differentiated neuroendocrine tumors metastatic to the liver: implications for prognostic stratification. Am J Surg Pathol 2011; 35:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/33\">",
"      Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol 2011; 29:2372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/34\">",
"      Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011; 29:3044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/35\">",
"      Dolcetta-Capuzzo A, Villa V, Albarello L, et al. Gastroenteric neuroendocrine neoplasms classification: comparison of prognostic models. Cancer 2013; 119:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/36\">",
"      Strosberg JR, Weber JM, Feldman M, et al. Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol 2013; 31:420.",
"     </a>",
"    </li>",
"    <li>",
"     Travis WD. The concept of pulmonary neuroendocrine tumours. In: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart, Travis WD, et al (Eds), IARC Press, Lyon, France 2004. p.19.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/38\">",
"      Travis WD, Rush W, Flieder DB, et al. Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 1998; 22:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/39\">",
"      Moran CA, Suster S. Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases. Am J Clin Pathol 2000; 114:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/40\">",
"      Brown DC, Gatter KC. Ki67 protein: the immaculate deception? Histopathology 2002; 40:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/41\">",
"      Yerushalmi R, Woods R, Ravdin PM, et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/42\">",
"      von Herbay A, Sieg B, Sch&uuml;rmann G, et al. Proliferative activity of neuroendocrine tumours of the gastroenteropancreatic endocrine system: DNA flow cytometric and immunohistological investigations. Gut 1991; 32:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/43\">",
"      Pelosi G, Bresaola E, Bogina G, et al. Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables. Hum Pathol 1996; 27:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/44\">",
"      La Rosa S, Klersy C, Uccella S, et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol 2009; 40:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/45\">",
"      Ohike N, Morohoshi T. Pathological assessment of pancreatic endocrine tumors for metastatic potential and clinical prognosis. Endocr Pathol 2005; 16:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/46\">",
"      Pape UF, Berndt U, M&uuml;ller-Nordhorn J, et al. Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 2008; 15:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/47\">",
"      Klimstra DS, Modlin IR, Adsay NV, et al. Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 2010; 34:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/48\">",
"      Couvelard A, Deschamps L, Ravaud P, et al. Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. Mod Pathol 2009; 22:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/49\">",
"      Lejeune M, Ja&eacute;n J, Pons L, et al. Quantification of diverse subcellular immunohistochemical markers with clinicobiological relevancies: validation of a new computer-assisted image analysis procedure. J Anat 2008; 212:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/50\">",
"      L&oacute;pez C, Lejeune M, Salvad&oacute; MT, et al. Automated quantification of nuclear immunohistochemical markers with different complexity. Histochem Cell Biol 2008; 129:379.",
"     </a>",
"    </li>",
"    <li>",
"     Tang LH, Gonen M, Hedvat C, et al. An objective assessment of Ki67 proliferative index quantification in gastroenteropancreatic neuroendocrine tumors (NETs) (Abstract #712). Mod Pathol 2011; 24:170A.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/52\">",
"      Deshpande V, Fernandez-del Castillo C, Muzikansky A, et al. Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol 2004; 28:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/53\">",
"      Zhang L, Smyrk TC, Oliveira AM, et al. KIT is an independent prognostic marker for pancreatic endocrine tumors: a finding derived from analysis of islet cell differentiation markers. Am J Surg Pathol 2009; 33:1562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/40/6794/abstract/54\">",
"      Shia J, Tang LH, Weiser MR, et al. Is nonsmall cell type high-grade neuroendocrine carcinoma of the tubular gastrointestinal tract a distinct disease entity? Am J Surg Pathol 2008; 32:719.",
"     </a>",
"    </li>",
"    <li>",
"     Tang L, Shia J, Vakiani E, et al. High grade transformation of differentiated neuroendocrine neoplasms (NENs) of the enteropancreatic system - a unique entity distinct from de novo high grade neuroendocrine carcinoma (HGNECa) in pathogenesis and clinical behavior (Abstract #622). Mod Pathol 2008; 21:137A.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14247 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-66B715A8D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_40_6794=[""].join("\n");
var outline_f6_40_6794=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H440387125\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H440387060\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H440387068\">",
"      PATHOLOGY, TUMOR CLASSIFICATION, AND NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H799304\">",
"      Morphology and immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H799311\">",
"      Classification",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2474971\">",
"      - Historical evolution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2474956\">",
"      - 2010 WHO classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H13525387\">",
"      Staging system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H799428\">",
"      - Functionality and nomenclature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H800434\">",
"      ISSUES RELATED TO ASSESSING GRADE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H440387075\">",
"      Assessment of mitotic activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H799582\">",
"      - Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H440387082\">",
"      Assessment of Ki67 labeling index",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H800183\">",
"      - Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H800190\">",
"      Choice of method",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H440387097\">",
"      Intratumoral heterogeneity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H440387111\">",
"      Other parameters and markers for histological grading",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H440387118\">",
"      POORLY DIFFERENTIATED NEUROENDOCRINE CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H440387125\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/14247\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14247|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/46/42734\" title=\"figure 1\">",
"      Kaplan-Meier survival curve metastatic well-differentiated NETs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14247|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/10/26794\" title=\"picture 1\">",
"      Histologic appearance of neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/19/40240\" title=\"picture 2\">",
"      Gastric carcinoid Gross",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/28/36292\" title=\"picture 3\">",
"      Photo well differentiated pancreatic NET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/35/15930\" title=\"picture 4\">",
"      Examples of well differentiated NETs of the digestive organs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/54/33642\" title=\"picture 5\">",
"      Example of intratumoral heterogeneity in digestive tract NETs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/14247|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/13/12508\" title=\"table 1\">",
"      Evolution WHO terminology for neuroendocrine tumors in GI tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/28/28107\" title=\"table 2\">",
"      AJCC criteria for histologic grade of neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/14/17644\" title=\"table 3\">",
"      Nomenclature and classification for neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/18/4397\" title=\"table 4\">",
"      TNM stage append carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/32/43532\" title=\"table 5\">",
"      TNM panc endo exo CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/55/41852\" title=\"table 6\">",
"      TNM stage gastric carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/15/42236\" title=\"table 7\">",
"      TNM gastrointest carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/22/2413\" title=\"table 8\">",
"      TNM staging CRC carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/6/33900\" title=\"table 9\">",
"      Characteristics of pancreatic neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/37/25181\" title=\"table 10\">",
"      Histologic grading for neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/18/39211\" title=\"table 11\">",
"      Intratumoral heterogeneity Ki67 grades",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/55/9082?source=related_link\">",
"      Bronchial carcinoid tumors: Epidemiology, risk factors, classification, histology, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/14/36074?source=related_link\">",
"      Cancer of the appendix and pseudomyxoma peritonei",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11400?source=related_link\">",
"      Diagnosis of the carcinoid syndrome and tumor localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/57/31640?source=related_link\">",
"      Glucagonoma and the glucagonoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12777?source=related_link\">",
"      Insulinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/46/39658?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/13/41174?source=related_link\">",
"      Neuroendocrine cancer of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42552?source=related_link\">",
"      Pathobiology and staging of small cell carcinoma of the lung",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/43/22201?source=related_link\">",
"      Pathology of lung malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/43/4794?source=related_link\">",
"      Pathology of mediastinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/34/3623?source=related_link\">",
"      Somatostatinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/59/16311?source=related_link\">",
"      The VIPoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/28/21962?source=related_link\">",
"      Thymic neuroendocrine (carcinoid) tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39897?source=related_link\">",
"      Treatment and surveillance of non-metastatic carcinoid tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_40_6795="Churg Strauss five factor score";
var content_f6_40_6795=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Five factor score in eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Cardiac involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrointestinal disease (bleeding, perforation, infarction, or pancreatitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal insufficiency (plasma creatinine concentration &gt;1.6 mg/dL [141 mmol/L])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Proteinuria (&gt;1 g/day)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Central nervous system involvement",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The presence of each factor is given one point. The FFS score ranges from 0 to 2: a score of 0 is given when none of the factors is present, a score of 1 for one factor, and a score of 2 for two or more factors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Guillevin L, Lhote F, Gayraud M, et al.. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine 1996; 75:17.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_40_6795=[""].join("\n");
var outline_f6_40_6795=null;
var title_f6_40_6796="ACR neuropsychiatric SLE";
var content_f6_40_6796=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51238&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Neuropsychiatric manifestations of systemic lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Central",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aseptic meningitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cerebrovascular disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Demyelinating syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Headache",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Movement disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Seizure disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myelopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Acute confusional state",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Anxiety disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cognitive dysfunction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mood disorder",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Psychosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Peripheral",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Guillain-Barre syndrome",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Autonomic neuropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Mononeuropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Myasthenia gravis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cranial neuropathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Plexopathy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Polyneuropathy",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999; 42:599.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_40_6796=[""].join("\n");
var outline_f6_40_6796=null;
var title_f6_40_6797="Lymph node invasion BE";
var content_f6_40_6797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lymph node invasion in surgical resection specimens of patients with early cancer in a Barrett's esophagus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Author (year)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Number of patients",
"      </td>",
"      <td class=\"subtitle1\">",
"       Selection criteria",
"      </td>",
"      <td class=\"subtitle1\">",
"       Number of lymph nodes resected",
"      </td>",
"      <td class=\"subtitle1\">",
"       Positive lymph node in T1m",
"      </td>",
"      <td class=\"subtitle1\">",
"       Survival in T1m",
"      </td>",
"      <td class=\"subtitle1\">",
"       Positive lymph node in T1sm",
"      </td>",
"      <td class=\"subtitle1\">",
"       Survival in T1smN1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Peters (1994)",
"      </td>",
"      <td>",
"       17",
"      </td>",
"      <td>",
"       Preoperative HGD/early cancer*",
"      </td>",
"      <td>",
"       --",
"      </td>",
"      <td>",
"       0/4 HGD 0/9 T1m",
"      </td>",
"      <td>",
"       100 percent 5-yr",
"      </td>",
"      <td>",
"       1/2",
"      </td>",
"      <td>",
"       --",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ruol (1997)",
"      </td>",
"      <td>",
"       26&bull;",
"      </td>",
"      <td>",
"       Postoperative diagnosis pT1",
"      </td>",
"      <td>",
"       --",
"      </td>",
"      <td>",
"       0/4",
"      </td>",
"      <td>",
"       94 percent 5-yr&Delta;",
"      </td>",
"      <td>",
"       8/22",
"      </td>",
"      <td>",
"       37 percent 5-yr",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nigro (1999)",
"      </td>",
"      <td>",
"       37",
"      </td>",
"      <td>",
"       Postoperative diagnosis pT1/2",
"      </td>",
"      <td>",
"       41&loz;",
"      </td>",
"      <td>",
"       1/15 T1m",
"      </td>",
"      <td>",
"       --",
"      </td>",
"      <td>",
"       6/12 T1sm",
"      </td>",
"      <td>",
"       --",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Nigro (1999)",
"      </td>",
"      <td>",
"       28",
"      </td>",
"      <td>",
"       Postoperative diagnosis pT1/2",
"      </td>",
"      <td>",
"       14&loz;",
"      </td>",
"      <td>",
"       0/13 T1m",
"      </td>",
"      <td>",
"       --",
"      </td>",
"      <td>",
"       1/6 T1sm",
"      </td>",
"      <td>",
"       --",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Van Sandick (2000)",
"      </td>",
"      <td>",
"       32",
"      </td>",
"      <td>",
"       Postoperative diagnosis pT1",
"      </td>",
"      <td>",
"       13&sect;",
"      </td>",
"      <td>",
"       0/12",
"      </td>",
"      <td>",
"       100 percent 3-yr",
"      </td>",
"      <td>",
"       6/20",
"      </td>",
"      <td>",
"       50 percent 3-yr",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Stein (2000)",
"      </td>",
"      <td>",
"       94",
"      </td>",
"      <td>",
"       Postoperative diagnosis pT1",
"      </td>",
"      <td>",
"       21 and 19&loz; + IHC",
"      </td>",
"      <td>",
"       0/38",
"      </td>",
"      <td>",
"       90 percent 5-yr",
"      </td>",
"      <td>",
"       10/56",
"      </td>",
"      <td>",
"       60 percent 5-yr",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rice (2001)",
"      </td>",
"      <td>",
"       122",
"      </td>",
"      <td>",
"       Postoperative diagnosis pT1",
"      </td>",
"      <td>",
"       --",
"      </td>",
"      <td>",
"       0/38 HGD 2/53 T1m",
"      </td>",
"      <td>",
"       95 percent 5-yr 80 percent 5-yr",
"      </td>",
"      <td>",
"       6/31",
"      </td>",
"      <td>",
"       25 percent TxN1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fernando (2002)",
"      </td>",
"      <td>",
"       28",
"      </td>",
"      <td>",
"       Preoperative HGD&yen;",
"      </td>",
"      <td>",
"       16&sect;",
"      </td>",
"      <td>",
"       0/17 HGD 0/6 T1m",
"      </td>",
"      <td>",
"       100 percent 1-yr",
"      </td>",
"      <td>",
"       1/5",
"      </td>",
"      <td>",
"       --",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HGD: high-grade dysplasia.",
"     <br>",
"      * Preoperative work-up: no review histology, Seattle Bx protocol, EUS not mentioned, inclusion: 1985-1993.",
"      <br>",
"       &bull; 11 cardia and 15 Barrett's lesions.",
"       <br>",
"        &Delta; For T1m/sm No.",
"        <br>",
"         &loz; Median.",
"         <br>",
"          &sect; Mean.",
"          <br>",
"           &yen; Preoperative work-up: review histology, four-quadrant Bx in 64 percent, EUS in 57 percent.",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Siersema PD, Rosenbrand CG, Bergman JJ, et al. (Guideline \"Diagnosis and treatment of oesophageal carcinoma\".) Ned Tijdschr Geneeskd 2006; 150:1877. Copyright &copy; 2006 Nederlands Tijdschrift voor Geneeskunde.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_40_6797=[""].join("\n");
var outline_f6_40_6797=null;
var title_f6_40_6798="Contents: Obstetrics, Gynecology and Women's Health";
var content_f6_40_6798=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      Obstetrics, Gynecology and Women's Health",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Obstetrics, Gynecology and Women's Health",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     You receive the entire UpToDate library of specialties with your ",
"							subscription. Click on a section below to view a detailed list of topics associated ",
"							with that particular section. If you'd like to see the table of contents for other ",
"							specialties,",
"     <a href=\"UTD.htm?3/3/3134\">",
"      click here",
"     </a>",
"     .",
"     <br/>",
"     <br/>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?27/50/28463\">",
"         Antenatal care",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?41/2/42031\">",
"         Breast cancer",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?17/61/18385\">",
"         Critical care obstetrics",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?32/63/33789\">",
"         Fetoplacental physiology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?22/6/22624\">",
"         General medical issues in women",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?14/33/14864\">",
"         Gynecologic oncology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?3/62/4078\">",
"         Gynecologic procedures",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?26/13/26847\">",
"         Gynecologic surgery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?12/44/13007\">",
"         Labor and delivery",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?36/53/37727\">",
"         Maternal medical problems",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?37/8/38018\">",
"         Neonatology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?27/20/27981\">",
"         Obstetrics calculators",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?3/56/3982\">",
"         Obstetrics procedures",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?40/28/41410\">",
"         Office gynecology",
"        </a>",
"        <br/>",
"       </tds>",
"       <tds valign=\"top\" width=\"33%\">",
"        <a class=\"tocItem\" href=\"UTD.htm?21/41/22174\">",
"         Postpartum issues",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?8/54/9057\">",
"         Pregnancy complications",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?12/47/13041\">",
"         Reproductive endocrine female",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?28/27/29118\">",
"         Urogynecology",
"        </a>",
"        <br/>",
"        <a class=\"tocItem\" href=\"UTD.htm?29/35/30264\">",
"         What's new in obstetrics and gynecology",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        &nbsp;",
"       </tds>",
"      </trs>",
"      <trs>",
"       <tds>",
"        <a class=\"tocItem\" href=\"UTD.htm?18/22/18798\">",
"         Patient Information",
"        </a>",
"        <br/>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-D7D71F1618-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f6_40_6798=[""].join("\n");
var outline_f6_40_6798=null;
var title_f6_40_6799="Survival with ICD in dialysis";
var content_f6_40_6799=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F72475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F72475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Estimated unadjusted survival of dialysis patients with and without an implantable cardioverter-defibrillator (ICD)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 406px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figure showing probability of survival over time among dialysis patients with a history of sudden cardiac death. At every time point, a higher unadjusted survival is observed in patients with an ICD (green line) compared with those without an ICD (black line).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Herzog, CA, Li, S, Weinhandl, ED, et al. Survival of dialysis patients after cardiac arrest and the impact of implantable cardioverter defibrillators. Kidney Int 2005; 68:818.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_40_6799=[""].join("\n");
var outline_f6_40_6799=null;
